

George H. Poste

CURRICULUM VITAE

Present Appointment:

George Poste, D.V.M., Ph.D, F.R.C. Path., F. Med Sci., CBE, F.R.S.
Director and Chief Scientist, Complex Adaptive Systems Initiative
Regents' Professor and Del E. Webb Chair in Health Innovation
Arizona State University
1475 N. Scottsdale Rd., Suite 361
Scottsdale, AZ 85257
Telephone: 480-727-8662
Fax: 480-884-2040
E-mail: george.poste@asu.edu
Website: <https://casi.asu.edu/presentations/>

Education, Qualifications and Honors:

1966	D.V.M.	University of Bristol, England (Veterinary Medicine) (Graduated first in class)
1966	M.R.C.V.S.	Member, Royal College of Veterinary Surgeons, London, England
1969	Ph.D.	University of Bristol, England (Virology)
1979	M.R.C. Path.	Membership, Royal College of Pathologists, London, England (Board Certification in Pathology)
1987	D.Sc.	University of Bristol, England. Distinguished Contributions to Research
1987	F.R.C.V.S.	Elected Fellow, Royal College of Veterinary Surgeons, London, England
1989	F.R.C. Path.	Elected Fellow, Royal College of Pathologists, London, England
1993	F.R.C.P. (Hon.)	Elected Fellow, Faculty of Pharmaceutical Medicine, Royal College of Physicians, London, England
1994	F.R.S.A.	Elected Fellow, Royal Society of Arts, Manufactures and Commerce, London, England
1995	LL.D. (Hon.)	University of Bristol, England
1997	F.R.S.	Elected Fellow, The Royal Society, London, England
1998	F.Med.Sci.	Elected Fellow, The Academy of Medical Sciences, London, England
1998	LL.D. (Hon.)	University of Dundee, Scotland
1999	C.B.E.	Commander of the Order of the British Empire, Honours List, H.M. Queen
1999	Honorary Fellow	University College London
2000	Member	Elected Member, Worshipful Company of Apothecaries, London
2004	Member	Council for Foreign Relations
2004	Award	Recipient of <i>Scientist of the Year</i> Award, R&D Magazine
2006	Award	Regents Professor, Arizona State University
2006	Award	Einstein Award, Global Business Leadership Forum
2009	Award	Scrip Lifetime Achievement Award from Pharmaceutical Industry Leadership Forum
2016	Award	2016 Arizona Bioindustry Association Pioneer Award for Lifetime Achievement
2019	Award	Member, EU Academy of Sciences
2021	Member	Elected Fellow, American Institute for Medical and Biological Engineering (AIMBE)
2021	Member	Global Futures Scientist, Julie Ann Wrigley Global Futures Laboratory

Previous Appointments:

2003 – 2009	Director, The Biodesign Institute, Arizona State University
2000 – 2003	Office of Secretary of Defense, Defense Science Board, Bioterrorism Task Force
2000 – 2003	Miscellaneous Board Responsibilities (see below)
1997 – 2000	Chief Science and Technology Officer, SmithKline Beecham, Philadelphia
1991 – 1997	President, Research and Development, SmithKline Beecham Pharmaceuticals, Philadelphia, PA
1989 – 1991	Executive Vice President, Research and Development, SmithKline Beecham Pharmaceuticals, Philadelphia, Pennsylvania
1988 – 1989	President, Research and Development, SmithKline & French Laboratories, Philadelphia, Pennsylvania
1987 – 1988	Vice President, Worldwide Research and Preclinical Development, SmithKline & French Laboratories, Philadelphia, Pennsylvania
1983 – 1986	Vice President, Research and Development, SmithKline & French Laboratories, Philadelphia, Pennsylvania
1980 – 1983	Vice President and Director of Research, SmithKline & French Laboratories, Philadelphia, Pennsylvania
1975 – 1980	Principal Cancer Research Scientist, Department of Experimental Pathology, Roswell Park Memorial Institute, Buffalo, New York and Professor, Department of Cell and Molecular Biology, State University of New York at Buffalo
1974	Senior Lecturer, Department of Virology, Royal Postgraduate Medical School, University of London, England
1972 – 1974	Associate Professor of Experimental Pathology, Roswell Park Memorial Institute, Buffalo, New York (On official leave of absence from the University of London)
1970 – 1972	Lecturer in Virology, Royal Postgraduate Medical School, London, England
1969 – 1970	Research Fellow, Department of Virology, Royal Postgraduate Medical School, University of London, England
1966 – 1969	Research Fellow and Assistant Lecturer, Department of Bacteriology, University of Bristol, England

Board Memberships:

1992 – 1999	Board Member, SmithKline Beecham (now GlaxoSmithKline)
2000 – 2003	Board Member, Illumina
2000 – 2003	Board Member, Maxygen
1997 – 2003	Chairman, diaDexus (acquired by VaxGen)
2000 – 2003	Chairman, Structural GenomiX (acquired by Eli Lilly)
2002 – 2005	Board Member, AdvancePCS (acquired by CVS-Caremark)
2002 – 2009	Chairman, Orchid Biosciences (acquired by LabCorp.)
2003 – 2018	Board Member, Monsanto (acquired by Bayer)
2004 – present	Board Member, Exelixis
2005 – present	Non-executive Vice Chairman, Caris Life Sciences
2008 – present	Haplogen Scientific Advisory Board
2009 – present	Scientific Advisory Board, Synthetic Genomics Inc.
2013 – present	Member, Governing Board, The Bulletin of The Atomic Scientists
2015 – present	Chair, Scientific Advisory Board, A. Alfred Taubman Institute, University of Michigan

Board Memberships Continued:

2016 – present	Member, MIDAS External Advisory Board, University of Michigan
2017 – present	Member, VirBiotech Scientific Advisory Board

Professional and Civic Duties:

1980 – 1983	Member, Pathology B Study Section, National Institute of Health
1980 – 1983	Member, Scientific Advisory Panel, Biological Response Modifiers Program, National Cancer Institute
1983 – 1986	Member, Committee du Direction, Centre Nationale de Recherche Scientifique, (CNRS), Republic of France
1984 – 1986	Member, Board of Governors, National Association for Biomedical Research
1985 – 1989	Trustee, Gordon Research Conferences
1985 – 1990	Member, UCLA Conferences Symposium Board
1986 – 1995	Member, Board of Directors, The Royal Society of Medicine Foundation
1987 – 1989	Chairman, Research and Development Section, Pharmaceutical Manufacturers Association
1987 – 1992	Member, Board of Overseers of the School of Veterinary Medicine, University of Pennsylvania
1987 – 1993	Trustee, Philadelphia College of Pharmacy and Science
1988 – 1992	Member, Executive Council, International Society for Differentiation
1987 – 1993	Trustee, Philadelphia College of Pharmacy and Science
1988 – 1992	Member, Executive Council, International Society for Differentiation
1988 – 1992	Member, Scientific Advisory Board, Institute for Scientific Information, Philadelphia
1988 – 1992	Member, President's Council, M.D. Anderson Cancer Center, University of Texas
1989 – 1991	Member, Scientific Committee, Association of the British Pharmaceutical Industry (ABPI)
1992 – 1996	Trustee, The Keystone Center, Keystone, Colorado
1993 – 1997	Member, Board of Directors, Alliance for Aging Research
1993 – 1997	Member, Governor's Task Force on Economic Development, Commonwealth of Pennsylvania
1994 – 1997	Member, Research-Intensive Industries Task Force, Institute for the Future, Menlo Park, CA
1993 - 2003	Member, Governing Board, Beckman Center for Molecular and Genetic Medicine, Stanford University
1998 – 1999	Member, Advisory Committee on Global R&D, Council on Competitiveness, Washington, DC
1998 – 1999	Member, Standing Group on Health Technology, National Health Service (UK)
1998 – 1999	Member, National Health Service Executive Standing Group on Technology Assessment (UK)
1998 – 1999	Member, Ministerial Competitiveness Working Party on Innovation, Department of Trade and Industry (UK)
1997 – 1999	Member, Human Genetics Advisory Commission (UK)
1998 – 2000	Member, BP Technology Advisory Council
1998 – 2000	Member, Board of Medical Governors, World Economic Forum, Davos
1998 – 2001	Member, Rand Critical Technologies Task Force on the Hybrid Carbon Silicon Brain
1993 – 2003	Member, Governing Board, Beckman Center for Molecular and Genetic Medicine, Stanford University
2000 – 2009	Member, Defense Science Board, United States Department of Defense
2001 – 2005	Member, Threat Reduction Advisory Committee, United States Department of Defense
2008 – 2020	Member, National Academy of Medicine, Forum on Microbial Threats

Current	Member, Expert Advisory Group. Analysis of the Influenza Vaccine Enterprise and Recommendations for the Future. The University of Minnesota, the Center for Infectious Disease Research and Policy (CIDRAP).
2021-Present	Member, Executive Committee, American Association for Cancer Research. Cancer Evolution Working Group

Professional and Civic Duties Continued:

Current	Chair, Scientific Advisory Board, A. Alfred Taubman Medical Research Institute, University of Michigan (AATMRI)
Current	Member, Wellcome Trust Ebola Vaccine Task Force
Current	Member, Department of Defense Blue Ribbon Panel for Review of the Veterans Administration Healthcare System
Current	Advisor, BiologyNext Initiative, In-Q-Tel, Inc.
Current	Member, Committee on a National Strategy for Cancer Control in the United States The National Academies of Sciences, Engineering, and Medicine (NASSEM)
Current	Member, One Health Action Collaborative (OHAC) of the National Academies' Forum on Microbial Threats
Current	Member, National Biomarker Development Alliance (NBDA)
Current	Member, One Health Action Collaborative (OHAC) of the National Academies' Forum on Microbial Threats
Current	Bipartisan Blue Ribbon Panel on Biodefense, Washington, D.C.
Current	Member, US Global Leadership Coalition, Arizona Advisory Committee

Editorial Responsibilities for Professional Publications:

1985 – 1996	Founder and Member, Editorial Board, Cancer and Metastasis Reviews
1987 – 1995	Member, Editorial Board, Cancer Invasion and Metastasis
1987 – 1999	Member, Editorial Board, Drug Targeting and Delivery
1988 – 1995	Member, Editorial Board, Clinical and Experimental Metastasis
1989 – 1999	Member, Editorial Board, International Journal of Pharmaceutics
1990 – 1998	Member, Editorial Board, Journal of Drug Targeting
1992 – 1999	Member, Editorial Board, Advanced Drug Delivery Reviews
Current	Member, Editorial Board, Nature Bio/Technology
Current	Member, Editorial Board, Current Opinion in Biotechnology
Current	Member, Editorial Board, Expert Opinion on Investigational Drugs
Current	Member, Senior Advisory Panel, Current Drugs
Current	Member, Editorial Board, Pharmacogenomics
Current	Member, Editorial Board, Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science
Current	Member, Editorial Board, Expert Opinion on Molecular Diagnostics
Current	Member, Editorial Board, BioTechniques
Current	Member, Editorial Board, Health Security, Mary Ann Liebert, Inc.

Club Memberships:

Current	Athenaeum, London
Current	Paradise Valley Country Club, Arizona

Published Works:

1. Poste, G., & Gillum, D. (2023, January 19). Researchers hacked a lab's pathogen containment system. Was it a good idea to publish the results? <https://thebulletin.org/>. Retrieved January 19, 2023, from <https://thebulletin.org/2023/01/researchers-hacked-a-labs-pathogen-containment-system-was-it-a-good-idea-to-publish-the-results/#post-heading>
2. Johns Hopkins Center for Health Security. (2022, July 8). Group of scientists, public health experts, policy researchers propose strengthening of US government's enhanced potential Pandemic Pathogen Framework and dual use research of concern policies. Johns Hopkins Center for Health Security. <https://www.centerforhealthsecurity.org/news/center-news/2022-07-08-ePPP-sign-on-letter.html>
3. Against Threats to Food and Agriculture. Washington, DC: Bipartisan Commission on Biodefense <https://biodefensecommission.org/reports/boots-on-the-ground-land-grant-universities-in-the-fight-against-threats-to-food-and-agriculture/>
4. Ex Officio Member: Bipartisan Commission on Biodefense. (2022). Boots on the Ground: Land-Grant Universities in the Fight
5. Ott, CM, et al., (2021). Vision for the Next Generation of Spaceflight Microbiology: Human Health and Habitat Sustainability. Decadal Survey on Biological and Physical Sciences Research in Space 2023-2032 conducted by the National Academies of Science, Engineering and Medicine. Washington D.C.
6. Nickerson, C.A., Medina-Colorado, A.A., Barrila, J. et al. A vision for spaceflight microbiology to enable human health and habitat sustainability. *Nat Microbiol* 7, 471-474 (2022). <https://doi.org/10.1038/s41564-021-01015-6>
7. Lennerz, J.K., Marble, H.D., Lasiter, L. et al. (2021). Do not sell regulatory science short. *Nat. Med.* <https://doi.org/10.1038/s41591-021-01298-6>
8. Ex Officio Member: Bipartisan Commission on Biodefense. (2021). Saving Sisyphus: Advanced Biodetection for the 21st Century. Washington, DC: Bipartisan Commission on Biodefense. <https://biodefensecommission.org/reports/saving-sisyphus-advanced-biodetection-for-the-21st-century/>
9. at Biological Risk. Bipartisan Commission on Biodefense: Washington, DC. <https://biodefensecommission.org/reports/insidious-scourge-critical-infrastructure-at-biological-risk/>
10. Bipartisan Commission on Biodefense. (2021). Insidious Scourge: Critical Infrastructure
11. Ex Officio Member: Bipartisan Commission on Biodefense. Biodefense in Crisis: Immediate Action Required to Address National Vulnerabilities. (2021). <https://biodefensecommission.org/reports/biodefense-in-crisis-immediate-action-needed-to-address-national-vulnerabilities/>
12. Ex Officio Member: The Apollo Program for Biodefense. Winning the Race Against Biological Threats. Bipartisan Commission Report. (2021) <https://biodefensecommission.org/reports/the-apollo-program-for-biodefense-winning-the-race-against-biological-threats/>
13. Moses, H., III and Poste, G. "Reducing Systemic Vulnerabilities in US Health Care." National Academy of Engineering: Winter Issue of The Bridge on Complex Unifiable Systems. (2020) 50, (4) 50-52., www.nae.edu/244717/Reducing-Systemic-Vulnerabilities-in-US-Health-Care.
14. Madhavan, G., Poste, G. and Rouse, W. (2020). Editors. National Academy of Engineering: Winter Issue of The Bridge on Complex Unifiable Systems., vol. 50, (4) <https://www.nae.edu/244665/Winter-Issue-of-The-Bridge-on-Complex-Unifiable-Systems>
15. Panel Member. Bipartisan Commission on Biodefense. Diagnostics for Biodefense - Flying Blind with No Plan to Land (2020) <https://biodefensecommission.org/reports/diagnostics-for-biodefense-flying-blind-with-no-plan-to-land/>
<https://www.newamerica.org/weekly/six-steps-to-fix-our-public-health-agencies-testing-capabilities-in-the-pandemic/>
16. Poste, G. (2020). Six Steps to Fix Our Public Health Agencies' Testing Capabilities in the Pandemic. New America,
17. Poste, G. (2020). Isaiah J. (Josh) Fidler, DVM, PhD, FAACR: In Memoriam (1936-2020)- A Visionary Research Career Dedicated to Understanding the Complexities of Cancer Metastasis. *Cancer Research*. DOI:10.1158/0008-5472.CAN-20-1905 <https://cancerres.aacrjournals.org/content/80/15/3059>
18. Committee Member (2020). A Strategy for the Future of the International Space Station (ISS) National Laboratory (ISSNL) and Commercial Low-Earth Orbit (LEO) Development.
19. Moses, H., III, Matheson, D.H.M. and Poste, G. (2019) "Serving Individuals and Populations Within Integrated Health Systems. A Bridge Too Far?" *JAMA*, 321, 1975, doi:10.1001/jama.2019.2929 <https://pubmed.ncbi.nlm.nih.gov/30920581/>
20. National Academies of Sciences, Engineering, and Medicine. (2019). Guiding Cancer Control: A Path to Transformation. Washington, DC: The National Academies Press. <https://doi.org/10.17226/25438>
21. Panel Member, Blue Ribbon Panel on Biodefense. Holding the Line on Biodefense. State, Local, Tribal, and Territorial Reinforcements Needed A Bipartisan Report of the Blue Ribbon Study Panel on Biodefense (2018). <https://www.biodefensestudy.org/Holding-the-Line-on-Biodefense>

22. Panel Member, Blue Ribbon Study Panel on Biodefense. Budget Reform for Biodefense: Integrated Budget Needed to Increase Return on Investment (2018). <https://biodefensecommission.org/reports/budget-reform-for-biodefense/>
23. Togami, E., J. L. Gardy, G. R. Hansen, G. H. Poste, D. M. Rizzo, M. E. Wilson, and J. A. K. Mazet. (2018). Core Competencies in One Health Education: What Are We Missing? NAM Perspectives. Discussion Paper, National Academy of Medicine Perspectives, Washington, DC. <https://nam.edu/core-competencies-in-one-health-education-what-are-we-missing>
24. Domenyuk, V., Gatalica, Z., Santhanam, R., Wei, X., Stark, A. Kennedy, P., Toussaint, B., Levenberg, S., Wang, J., Nianqing, X., Greil, R., Rinnerthaler, G., Gampenrieder, S., Heimberger, A., Berry, D., Barker, A., Quackenbush, J., Marshall, J., Poste, G., Vacirca, J., Vidal, G., Schwartzberg, L., Halbert, D., Voss, A., Magee, D., Miglarese, M., Famulok, M., Mayer, G., and Spetzler, D. "Poly-Ligand Profiling Differentiates Trastuzumab-Treated Breast Cancer Patients According to their Outcomes" *Nature Communications* (2018) <https://www.nature.com/articles/s41467-018-03631-z>
25. Panel Member. Bipartisan Commission on Biodefense. Diagnostics for Biodefense Defense of Animal Agriculture (2017) <https://biodefensecommission.org/reports/defense-of-animal-agriculture/>
26. MacIntyre, C. R., Engells, T. E., Scotch, M., Heslop, D. J., Gumel, A. B., Poste, G., Chen, X., Herche, W., Steinhöfel, K., Lim, S., and Broom, A. "Converging and Emerging Threats to Health Security" *Environment System Decisions*, (2017). <https://doi.org/10.1007/s10669-017-9667-0>
27. Alexander, B. M., Ba, S., Berger, M. S., Berry, D. A., Cavenee, W. K., Chang, S. M., Cloughesy, T. F., Jiang, T., Khasraw, M., Li, W., Mittman, R., Poste, G. H., Wen, P. Y., Yung, W. K. A., and Barker, A. D. "Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE" *Clinical Cancer Research* 24(3) (2017) DOI: 10.1158/1078-0432.CCR-17-0764 <https://clincancerres.aacrjournals.org/content/clincanres/24/4/737.full.pdf>
28. Poste, G. (2017). "The Complex Strategic Landscape for Precision Medicine: Cost, Convergence, Culture, Computing and Creative Destruction" *Journal of Precision Medicine*, 3, 36-51. <http://www.thejournalofprecisionmedicine.com/archive-manager/the-complex-strategic-landscape-for-precision-medicine-cost-convergence-culture-computing-and-creative-destruction/>
29. Domenyuk, V., Zhong, Z., Stark, A., Xiao, N., O'Neill, H. A. Wei, X., Wang, J., Tinder, T. T., Tonapi, S., Duncan, J., Hornung, T., Hunter, A., Miglarese, M. R., Schorr, J., Halbert, D. D., Quackenbush, J., Poste, G., Berry, D. A., Mayer, G., Famulok, M., and Spetzler, D. (2017) "Plasma Exosome Profiling of Cancer Patients by a Next Generation Systems Biology Approach" *Nature Scientific Reports* | 7:42741 | DOI: 10.1038/srep42741
DOI: 10.1080/2162402X.2016.1145332
30. D.A., Okada, H., and Heimberger, A.B. "Prioritization Schema for Immunotherapy Clinical Trials in Glioblastoma." *OncoImmunology* 5, 6 (2016)
31. Hodges, T.R., Ferguson, S.D., Caruso, H.G., Kohanbash, G., Zhou, S., Cloughesy, T.F., Berger, M.S., Poste G.H., Khasraw, M., Ba, S., Jiang, T., Mikkelsen, T., Yung, W. K., de Groot, J.F., Fine, H., Cantley, L.C., Mellinghoff, I.K., Mitchell,
32. Panel Member (2015) Bipartisan Report of the Blue Ribbon Panel on Biodefense (<http://nebula.wsimg.com/1616758492e7f6342ad285ddb1672f8?AccessKeyId=79611428B2C150CC86EA&disposition=0&alloworigin=1>)
33. Member, Veterans Choice Act, Blue Ribbon Panel. "Independent Assessment of the Health Care Delivery Systems and Management Processes of the Department of Veterans Affairs. Veterans Access, Choice, and Accountability Act of 2014" Section 201. Prepared by the Department of Veterans Affairs. A Product of the CMS Alliance to Modernize Healthcare Federally Funded Research and Development Center, (2015). Print. Volume I: Integrated Report. Task Order No. VA118A14F0373-384.
34. Osterholm, M., Moore, K., Ostrowsky, J., Kimball-Baker, K., Farrar, J., and Wellcome Trust-CIDRAP Ebola Vaccine Team B (Poste, G.). (2015) The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats. *Lancet Infectious Diseases* 16(1). (2015) (DOI:)
35. Castillo-Chavez, C., Curtiss, R., Daszak, P., Levin, S., Patterson-Lomba, O., Perrings, C., Poste, G., and Towers, S. (2015) "Beyond Ebola: Lessons to Mitigate Future Pandemics" *The Lancet Global Health* 3(7).
36. Member, International Ebola Vaccine Team Report. (2015) "Recommendations for Accelerating the Development of Ebola Vaccines: Report & Analysis" http://www.cidrap.umn.edu/sites/default/files/public/downloads/ebola_virus_team_b_report-final-021615.pdf.
37. Life Science Leader. From <http://www.lifescienceleader.com/doc/precision-oncology-big-data-and-analytics-come-to-cancer-care-0001>
38. Poste, G. (2014). Precision Oncology: Big Data And Analytics Come To Cancer Care.
39. Barker A., Compton C., Poste G. (2014) The National Biomarker Development Alliance (NBDA): Accelerating the Translation of Biomarkers to the Clinic. *Biomarkers Med.* 8(6), 873-876 <http://www.futuremedicine.com/doi/pdf/10.2217/bmm.14.52>
40. Poste G., Barker A., Compton C. (2014) The National Biomarker Development Alliance (NBDA): Confronting the Poor Productivity of Biomarker Research and Development. *Expert Rev. Mol. Diagn.* (doi:10.1586/14737159.2015.974561)
41. Interview George Poste: One step ahead (2013) *Bulletin of the Atomic Scientists* 69, 6, 1-10

42. Lindor, R.A., Allocco, S.J., Cheatham, L., Cortese, D.A., Hall, F.H., Mangold Jr., W.J., Pizziconi, V., Poste, G., Quinn, B., Roth, M., Saks, M.J., Wassman, E.R., Woosley, R.L., and Marchant, G. (2013) Regulatory and Reimbursement Innovation for Molecular Diagnostics: Parallel Review and Coverage with Evidence Development. *Sci Transl Med.* 5, 176, p. 176cm3.
43. Poste, G. (2012) Biospecimens, biomarkers, and burgeoning data: the imperative for more rigorous research standards. *Trends in Molecular Medicine.* 18, pp. 717-722
44. Adalja A.A., Wollner S. B., Inglesby T.V., Poste, G. (2012) The Globalization of US Medical Countermeasure Production and Its Implications for National Security. *Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science.* 10(3): 255-257.
http://www.kauffman.org/~media/kauffman_org/research%20reports%20and%20covers/2012/04/valuing_health_care.pdf
45. Poste, G. (2012) Member, Kauffman Task Force on Cost-Effective Health Care Innovation. Report "Valuing Health Care: Improving Productivity and Quality"
46. Poste, G., Carbone, D.P., Parkinson, D.R., Verweji, J., Hewitt, S.M., Jessup, J.M. (2012) Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development. *Clin. Cancer Res.* 18:1515-1523. DOI: 10.1158/1078-0432.CCR-11-2206
47. Poste, G. (2011) US Patent No. 7888035, Klass et al., Date of Patent Feb. 15, 2011
48. Poste, G. (2011) Bring on the biomarkers. *Nature.* 469, 156-157
49. Poste, G. (2009) Panel Member, The Institute of Medicine's (IOM's) Forum on Infectious Diseases, The Domestic and International Impacts of the 2009-H1N1 Influenza A Pandemic: Global Challenges, Global Solutions. Workshop Summary National Academies Press. ISBN-13: 978-0-309-14677
50. Poste, G. (2009) What's in a name? *Nature Biotechnology.* 27, 1071-1073
51. Claudia Acquisti, George Poste, David Curtiss, Sudhir Kumar (2007) Nullomers: Really a Matter of Natural Selection? *PLoS ONE.* 2(10): e1022. doi:10.1371/journal.pone.0001022
52. Poste, G. (2006) Animal Testing a Necessary Research Tool, For Now. *Arizona Republic*, September 3, 2006.
53. Poste, G (2005) Incorporating appropriate technology into North American schools of public health, *Pan Am JPublic Health* 19(2), 2005
54. Poste, G. (2005) Issues in Bioterrorism and Defense: A View of the Future in Technology Futures and Global Power, Wealth and Conflict. Ed. A.K. Solomon. Center for Strategic and International Studies (CSIS), Washington, DC.
55. Committee Member, (2006) Institute of Medicine and National Research Council Report: Globalization, Biosecurity and the Future of the Life Sciences. Washington, DC
56. Committee Member, (2005) Institute of Medicine and National Research Council Report. An International Perspective on Advancing Technologies and Strategies for Managing Dual-Use Risks. National Academy Press, Washington, DC.
57. Poste, G (2003) Genes and Molecular Medicine Proceedings of Cambridge Symposium to Celebrate 50 Years of the Double Helix. MRC Laboratory of Molecular Biology, Cambridge. Pp 16-21.
58. Bootman, J.L., Eichler, H-G., Jonsson, B., Moerman, D. and Poste, G. (2003). Achieving the value of medicines. International Forum on Medicines - International Pharmaceutical Federation, The Hague, The Netherlands.
59. Eichler, H-G., Bootman, J.L., Jonsson, B., Moerman, D., and Poste, G. (2003). The need to assess the value of medicines. International Forum on Medicines - International Pharmaceutical Federation, The Hague, The Netherlands.
60. Bootman, J.L., Eichler, H-G, Jonsson, B., Moerman, D., Poste, G., Kielgast, P., Hock, T. and Sousa-Pinto, G. (2003). An agenda for health priorities. International Forum on Medicines - International Pharmaceutical Foundation, The Hague, The Netherlands.
61. Member, Journal and Editors Group: National Academy of Science and Center for Strategic and International Studies Panel (2003) "Statement on Scientific Publication and Security". *Proc. Nat. Acad. Sci. USA* 100, 464 and *Nature* 421, 771.
62. Committee Member, (2003) National Research Council. Sharing Publication-Related Data and Materials: Responsibilities of Authorship in the Life Sciences. Washington, DC: The National Academies Press,
63. Poste, G. (2002) Biotechnology, Bioterrorism and Biosecurity. *Drug Discovery World.* Summer 2002, pp. 9-21.
64. Poste, G. (2002) Facing Reality in Preparing for Biological Warfare. *Health Affairs* 21.
65. Poste, G. (2002) Biotechnology and Terrorism. *Prospect.* #74, 48-52.
66. A Rude Awakening to the Forces of Good and Evil. *Financial Times Biotechnology Survey.* 27 November 2001.
67. The Dawning Life Sciences Defense Industry. An Interview with George Poste. *In Vivo* 2001 19 (9) 1-9.
68. Poste, G. (2001) Molecular diagnostics: a powerful new component of the healthcare value chain. *Expert Rev. Mol. Diag.* 1, 1-5.
69. Poste, G (2001) Genomics at the Cutting Edge. *Financial Times* 26 September 2001.
70. Poste, G. (2000) Biotechnology and the Evolution of Molecular Medicine. *J. Biolaw Supplement* 2000, 12-16.
71. Poste, G. (2000) The Nation is Falling Apart. *Financial Times* 4 December 2000

72. Poste, G. (2000) R&D in the Post-Genome World: The Challenge of Systems Biology, Financial Times Biotechnology Survey 16 November 2000.
73. Poste, G. (2000) Revealing Reality Within a Body of Imaginary Things. Essays for Theories, Models, Methods, Approaches, Assumptions and Findings". Catalog for Damien Hirst Exhibition, Gagosian Gallery, New York, September 2000
74. Fears, R., Roberts, D. Poste, G. (2000) Rational or rationed medicine? The promise of genetics for improved clinical practice. BMJ, April 2000, pp. 933-935.
75. Poste, G. (2000) The First battleground for the regulation of e.commerce. Financial Times 6 April 2000, Life Sciences Supplement IV.
76. Poste, G. (2000) The right treatment, for the right disease, for the right patient. Scrip Magazine, January, Issue 86.
77. Poste, G. (1999) The new risks to scientific progress, Financial Times, Life Sciences Supplement, 28 October, p. VII.
78. Poste, G., Bell, J., Davies, K., Goodfellow, P. and Hastie, N. (1999) Editors. Impact of genomics on healthcare. British Medical Bulletin, 55 (2), Royal Society of Medicine Press, London, 496 pp.
79. Fears, R., Weatherall D. and Poste, G. (1999) The impact of genetics on medical education and training. British Medical Bulletin, 55 (2), pp. 460-70.
80. Fears, R. and Poste, G. (1999) SmithKline Beecham and the future direction of medical research. Science in Parliament, Summer Issue, 56 (3), 10-11.
81. Poste, G. and Fears, R. (1999) The best ways forward. Science & Public Affairs, Special Issue, June, pp. 4-5.
82. Poste, G. (1999) Making more of yourself. Financial Times, Life Sciences Supplement, 15 July, p. 6.
83. Poste, G. and Fears, R. (1999) How to maximise the benefits of molecular medicine: integrated system to promote progress. UK Houses of Parliament, Biotechnology Supplement, May 3, pp. 12-3.
84. Poste, G. (1999) Not invented here: the old bromide has run its course, probably forever. The Genesis Report/Rx, February 8(2), 8-9.
85. Fears, R. and Poste, G. (1999) Building population genetics resources using the U.K. NHS. Science, 284, 267-68.
86. Poste, G. (1999) Antibiotic armageddon. Financial Times, Post Script, March 15, p. 6.
87. Ruffolo, Jr., R.R., Feuerstein, G.Z., Hunter, A.J., Poste and G. Metcalf, B.W. (1999) Inflammatory cells and mediators in CNS diseases. New Horizons in Therapeutics, Harwood Academic Publishers, The Netherlands.
88. Poste, G. and Fears, R. (1999) Joining up for the genome. Times Higher, Educational Supplement 19, February, pp. 40-1.
89. Fears, R. and Poste, G. (1998) British science policy: reasons to be cheerful and careful. Science and Public Affairs, The British Association, Winter Issue.
90. Poste, G. (1998) Science, Innovation and the Evolution of Genetic Medicine. European BioPharmaceutical Review, December, pp. 62-8.
91. Feuerstein, G.Z., Poste, G., Shusterman, N.H. and Ruffolo, Jr., R.R. (1998) The changing paradigm for pharmacotherapy of congestive heart failure. International Journal of Cardiovascular Medicine and Science, 1, 171-89.
92. Poste, G. (1998) Molecular medicine and information-based targeted healthcare. Nature Biotechnology, 16 (Supplement), 19-21.
93. Poste, G. (1998) New frontiers, new hurdles. The Parliament Magazine, May 4, p. 12.
94. Poste, G. (1998) Hard choices must be made for a competitive future. Research Fortnight, February 11, p. 13.
95. Yue, T-L, Ma, X-L, Wang, X., Romanic, A.M., Liu, G-L, Louden, C., Gu, J-L, Kumar, S., Poste, G. Ruffolo, Jr. and R.R. Feuerstein, G.Z. (1997) Possible involvement of stress-activated protein kinase signaling pathway and fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circulation Research, 82, 166-74.
96. Ruffolo, Jr., R.R., Poste, G. and Metcalf, B. (1997) Editors. Cell cycle regulation. New Horizons in Therapeutics, Harwood Academic Publishers, The Netherlands.
97. Poste, G. (1997) Science, medicine and society: progress, perils, opportunities and opponents. Vital Speeches of the Day, LXIII (24), 755-58.
98. Poste, G. (1997) In praise of excellence. Financial Times, Invited Editorial, August 1, p. 16.
99. Poste, G., Roberts, D. and Gentry, S. (1997) Patents, ethics and improving healthcare. Bulletin of Medical Ethics, 124, 29-31.
100. Fears, R., Ferguson, M.W.J., Stewart W. and Poste, G. (1997) Life-sciences R&D, national prosperity, and industrial competitiveness. Science, 276, 759-60.
101. Poste, G. (1997) Looking back to the future: healthcare by 2022. Scrip Magazine, April, p. 34-7.
102. Poste, G. (1997) Managing discontinuities in healthcare markets and technology. Vital Speeches of the Day, LXIII (10), 309-13.
103. Chopra, I., Hodgson, J., Metcalf, B. and Poste, G. (1997) The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicrobial Agents and Chemotherapy, 41, 497-503.

104. Poste, G. (1997) The science of the possible. *Times Higher*, February, p. 12.
105. Poste, G. (1997) Fight for your future. *Pharmaceutical Times*, January, p. 40.
106. Greller, L.D., Tobin, F.L. and Poste, G. (1996) Tumor heterogeneity and progression: conceptual foundations for modeling. *Invasion & Metastasis*, 16, 177-208.
107. Feuerstein, G.Z., Shusterman, N.H., Poste, G., Ruffolo, Jr., R.R. (1996) Beta-blockers and heart failure rationale and highlights and highlights from the carvedilol heart failure trials. *Pharmaceutical News*, 3, 18-23.
108. Poste, G. (1996) A strategy to promote a national asset. *Financial Times*, Invited Editorial, July 19, p. 12.
109. Poste, G. (1996) An acid test for excellence. *Financial Times*, Invited Editorial, June 7, p. 16.
110. Fears, R. and Poste, G. (1996) Challenges in R&D. *Science and Parliamentary Affairs*, Summer Issue, pp. 5-6.
111. Poste, G. (1996) Is SmithKline's future in its genes? *Business Week*, March 4, pp. 80-1.
112. Chopra, I., Hodgson, J. Metcalf, B., and. Poste, G., (1996) New approaches to the control of infections caused by antibiotic-resistant bacteria. *Journal of the American Medical Association*, 275, 401-03.
113. Poste, G. and McCormick D. (1995) Genomics: history and science in the making. *The Biotechnology Report*, (ed. H. Price), pp. 68-9. Campden Publishing Limited, London.
114. Greller, L.D., Tobin, F.L. and Poste, G. (1995) Computational tumor heterogeneity and progression. *Computational Medicine, Public Health, and Biotechnology (Part 1)*. (ed. M. Witten), 5, pp. 413-41. World Scientific Publishing Company, New Jersey.
115. interactions in tumor dynamics. *International Workshop on Information Processing in Cells and Tissues*, pp. 569-73. The University of Liverpool, England.
116. Greller, L.D., Tobin, F.L., Poste, G. and Wang, X. (1995) Genetic instability and progression
117. Fears, R and Poste G. (1995) Enabling the future: an industry perspective on the foresight science policy exercise in the life sciences. *Science Technology and Innovation*, 8, 26-30.
118. Poste, G. (1995) The case for genomic patenting. *Nature*, 378, 534-6.
119. Poste, G. (1995) There was a false comfort in healthcare. *Pharmaceutical Times*, October, 28-34.
120. Warner, M. and Poste, G. (1995) Editors. The impact of the new genetics on the NHS. *The Cardiff Debate*, Welsh Health Planning Forum, Cardiff, Wales.
121. Feuerstein, G.Z., Poste, G. and Ruffolo, Jr., R.R. (1995) Carvedilol update III: rationale for use in congestive heart failure. *Drugs of Today*, 31, 307-26.
122. Poste, G. (1995) Science: The view from industry. *Times Higher*, Education Supplement, April 21, 1995, p. 11.
123. Poste, G. (1995) The study of genes and their functional regulation. *Vital Speeches of the Day*, LXI (6), 165-69.
124. Gregoriadis, G., McCornack, B., Poste, G. (1994) Editors. Targeting of Drugs. *Advances in system constructs. NATO ASI Series. Series A: Life Sciences*, Vol. 273, Plenum Press, New York.
125. Ohlstein, E.H., Nambi, P., Douglas, S.A., Edwards, R.M., Gellai, M., Lago, A., Leber, J.D., Cousins, R.D., Gao, A., Frazee, J.S., Peishoff, C.E., Bean, J.W., Eggleston, D.S., Elshourbagy, N.A., Kumar, C., Lee, J.A., Yue, T-L., Loudon, C., Brooks, D.P., Weinstock, J., Feuerstein, G., Poste, G., Ruffolo, Jr., R.R., Gleason, J.G., Elliott, J.D. (1994) SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. *Proceedings of the National Academy of Sciences*, 91, 8052- 8056.
126. Ruffolo, Jr., R.R. and Poste, G. (1994) A prescription for better prescriptions: a response. *Issues in Science and Technology*, Summer Supplement, p. 9.
127. Poste, G. (1994) This house believes the NHS can no longer afford the best medicines. *The Great Oxford Debate. Pharmaceutical Times*, November, pp. 26-29.
128. Poste, G. and Fears, R. (1994) Industry's crystal ball. *Science & Public Affairs*, Autumn, pp. 4-6.
129. Fears, R., Greig, R., Poste, G. (1994) Human genomic research and innovative medicine. *Science in Parliament*, 51, 4-5.
130. Poste, G. (1994) R&D strategies in the pharmaceutical industry. *R&D Efficiency*, 3, 1-8.
131. Fears, R. and Poste, G. (1994) Obstacles to the development of novel thrombolytic agents for acute myocardial infarction therapy: is the good the enemy of the best? *Fibrinolysis*, 8, 214-20.
132. Fan, D., Poste, G., Seid, C., Earnest, L., Bull, T., Clyne, R., and Fidler, I. (1994) Reversal of multidrug resistance in murine fibrosarcoma cells by thioxanthene flupentixol. *Investigational New Drugs*, 12, 185-95.
133. Fears, R., Suckling K. and Poste, G. (1994) Novel agents in the treatment of atherosclerosis. *Exp. Opin. Invest. Drugs*, 3, 481-91.
134. Metcalf, B., Dalton, B.J., Poste, G. (1994) Editors. Cellular adhesion: molecular definition to therapeutic potential. *New Horizons in Therapeutics*, Plenum Press, New York.
135. -adrenoceptor antagonist furobenzazepine. *International Journal of Oncology*, 4, 789-98.
136. I.J. (1994) Circumvention of multidrug resistance in murine fibrosarcoma and colon carcinoma cells by treatment with the

137. Fan, D., Poste, G., Ruffolo, Jr., R.R., Dong, Z., Seid, C., Earnest, L.E., Campbell, T.E., Clyne, R.K., Belltran, P.J., Fidler, I.J. (1993) Editors. New generation vaccines. The role of basic immunology. NATO ASI Series. Series A: Life Sciences. Vol 261. Plenum Press, New York.
138. Gregoriadis, G., McCormack, B., Allison, A.C., Poste, G. (1993) Editors. New generation vaccines. The role of basic immunology. NATO ASI Series. Series A: Life Sciences. Vol 261. Plenum Press, New York.
139. Poste, G., (1993) Defining a strategy for healthcare research & development in turbulent times. *Pharmaceutical Forum*, Issue 2, pp. 11-15. Amersham International plc, Little Chalfont (UK).
140. Poste, G., (1993) Genetics, economics and ethics: the new trinity shaping the future direction of healthcare. *Campaign for Resource*. pp. 1-8, University of Bristol, London, England.
141. Smith, R.A.G., Dewdney, J.M., Fears, R., and Poste, G. (1993) Chemical derivatization of therapeutic proteins. *Trends in Biotechnology*, 11(9), pp. 397-403. Elsevier Science Publishers Ltd. (UK).
142. Ohlstein, E.H., Douglas, S.A., Sung, C.P., Yue, T.L., Loudon, C., Arleth, A., Poste, G., Ruffolo, Jr., R.R., Feuerstein, G.Z. (1993) Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration and neointimal formation following vascular injury. *Proceedings of the National Academy of Sciences*, Vol. 90, pp. 6189-93.
143. Fan, D., Poste, G., O'Brian, C.A., Seid, C., Ward, N.E., Earnest, L.E., Fidler, I.J. (1992) Chemosensitization of murine fibrosarcoma cells to drugs affected by the multidrug resistance phenotype by the antidepressant trazodone: an experimental model for the reversal of intrinsic drug resistance. *International Journal of Oncology*, 1, 734-42. National Hellenic Research Foundation, Athens, Greece.
144. Nichols, A.J., Ruffolo, Jr., R.R., Huffman, W.F., Poste, G. and Samanen, J. (1992) Development of GPIIb/IIIa antagonists as antithrombotic drugs. *Trends in Pharmacological Sciences*, Vol. 13, pp. 413-17. Elsevier Science Publishers Ltd. (UK).
145. Ruffolo, Jr., R.R., Boyle, D.A., Brooks, D.P., Feuerstein, G.Z., Venuti, R.P., Lukas, M.A., Poste, G. (1992) Carvedilol: a novel cardiovascular drug with multiple actions. *Cardiovascular Drug Reviews*, Vol. 10, No. 2, pp. 127-57. Neva Press, Inc.
146. Gregoriadis, G., Florence, A.T., Poste, G. (1991) Editors. Targeting of drugs 3: the challenges of peptides and proteins. NATO ASI Series. Series A: Life Sciences. Vol 238. Plenum Press, New York.
147. Brawner, M., Fornwald, J., Rosenberg, M., Poste, G. and Westpheling, J. (1991) *Streptomyces*: a host for heterologous gene expression. *Current Opinion in Biotechnology*, Vol. 2, pp. 674-81. Current Biology Ltd., London.
148. Brawner, M., Fornwald, J., Rosenberg, M., Poste, G. and Westpheling, J. (1990) Heterologous gene expression in streptomyces. *Genetics of Industrial Microorganisms*, pp. 85-93. Heslot, H., Davies, J., Florent, J., Bobichon, L., Durand, G., Penasse, L., (1990) Editors. *Societe Francaise de Microbiologie*, Strasbourg.
149. Gregoriadis, G., Allison, A., and Poste, G. (1990) Editors. Vaccines: recent trends and progress. NATO ASI Series. Series A: Life Sciences, Vol. 215. Plenum Press, New York.
150. Harris, T., Poste, G. (1991). Pharmaceutical applications. *Current Opinion in Biotechnology*, Vol. 2, No. 2, pp. 211-214. (ed. J. Davies) Current Biology Ltd., London.
151. Hanna, N., Poste, G. (1991). Inflammation. *Encyclopedia of Human Biology*, Vol. 4, pp. 469-477. Academic Press, New York.
152. Ruffolo, Jr., R.R., Brooks, D., Huffman, W., Poste, G., (1991) From vasopressin antagonist to agonist: a saga of surprise! *Drug News & Perspectives*, 4(4), 217-222.
153. Poste, G., The importance of the national climate as a stimulus to research in the USA. Reprinted from *Creating the Right Environment for Drug Discovery*, Edited by Stuart R. Walker, pp. 105-121. The Ciba Foundation, London. Quay Publishing.
154. Gregoriadis, G., Allison, A.C., Poste, G. (1989) Editors. Targeting of drugs 2: optimization strategies. NATO ASI Series. Series A: Life Sciences Vol. 199. Plenum Press, New York.
155. Hook, J., and Poste, G. (1990) Editors. Protein Design and the Development of New Therapeutics and Vaccines. Plenum Press, New York.
156. Greig, R., and Poste, G. (1990) Glycoconjugates as drugs. *Glycobiology*, pp. 173-193.
157. Badger, A.M., Griswold, D.E., Poste, G., Hanna, N. (1990) Histamine modulation of murine suppressor cell function. *Histamine & H2 Antagonists in Inflammation and Immunodeficiency*, pp. 3-21.
158. Gregoriadis, G., Allison, A.C., Poste, G. (1989) Editors. Immunological Adjuvants and Vaccines. NATO ASI Series. Series A: Life Sciences, Vol. 179.
159. Moyer, M.P., and Poste, G. (1989) Editors. Colon Cancer Cells. Academic Press, New York.
160. Bugelski, P.J., Gennaro, D.E., Poste, G., Hoffstein, S.T. (1989) A new cytochemical method for ultrastructural detection of liposomes in tissues in vivo. *Journal of Histochemistry and Cytochemistry*, 37(6) 843-851.
161. Pritchard, M.L., Rieman, D., Feild, J., Kruse, C., Rosenberg, M., Poste, G., Greig, R.G., Ferguson, B.Q. (1989) A truncated v-abl-derived tyrosine-specific tyrosine kinase expressed in escherichia-coli. *Biochem J.*, 257(2), 321-329.
162. Poste, G. (1989) Biotechnology: A new horizon for pharmacy. *U.S. Pharmacist* 14, 76-83.
163. Fidler, I., Poste, G., Murine Melanoma Metastasis. (1988) *ISI Atlas of Science: Immunology*, pp. 133-137.
164. Gregoriadis, G., Poste, G. (1988) Editors. Targeting of Drugs: Anatomical and Physiological Considerations. (1988) NATO ASI Series. Series A: Life Sciences, Vol. 155.

165. Poste, G., Greig, R. (1988) New-wave cancer therapy: Disease-specific strategies. *The Scientist*, 2(19), 1-14.
166. Caltabiano, M.M., Poste, G., Greig, R.G. (1988) Isolation and immunological characterization of the mammalian 32-/34- kDa stress protein. *Experimental Cell Research*, 178, 31-40.
167. Kruse, C.H., Holden, K.A., Offen, P.H., Pritchard, M.L., Feild, J.A., Rieman, D., Bender, P.E., Greig, R.G. and Poste, G. (1988) Synthesis and evaluation of multisubstrate inhibitors of an oncogene-encoded tyrosine-specific protein kinase. *J. Medicinal Chemistry*. 31, 1762-1772
168. Caltabiano, M.M., Poste, G., and Greig, R.G. (1988) Induction of the 32-kDa human stress protein by auranofin and related triethylphosphine gold analogs. *Biochem. Pharmacol.* 37, 21, 4089-4093.
169. Kirsh, R., Goldstein, R., Tarloff, J., Parris, D., Hook, J., Hanna, N., Bugelski, P., and Poste, G. (1988) An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. *The Journal of Infectious Diseases*, 158, 5, 1065-1070.
170. Young, J.F., and Poste, G. (1988) The prospects for a human malaria vaccine. *Trends in Biotechnology* 6, 63-68.
171. Trainer, D., Kline, T., Hensler, G., Greig, R., and Poste, G. (1988) Clonal analysis of the malignant properties of B16 melanoma cells treated with the DNA hypomethylating agent 5-azacytidine. *Clin. Expl. Metastasis* 6, 185-200.
172. Poste, G. and Crooke, S.T. (1988) Editors. Cellular and molecular aspects of inflammation. *New Horizons in Therapeutics Volume 5*, Plenum Press, New York.
173. Trainer, D.L., Kline, T., McCabe, F.L., Faucette, L.F., Feild, J., Chaikin, M., Anzano, M., Rieman, D., Hoffstein, S., Li, D., Gennaro, D., Buscarino, C., Lynch, M., Poste, G., and Greig, R. (1988) Biological characterization and oncogene expression in human colorectal carcinoma cell lines. *Int. J. Cancer* 41, 287-296.
174. Bailey, D.S., Nambi, P., Bryant, S.L., Clark, R.K., Trainer, D., Poste, G., Greig, R. (1987) Signal transduction and differentiation of colon carcinoma cells. *J. Cell Biol.*, Vol. 105.
175. Greig, R.G., Anzano, M., Tainer, D., Poste, G. (1987) Growth-regulation in colon-carcinoma. *Journal of Cellular Biochemistry*. S11D, p. 85.
176. Trainer, D.L., Clark, R., Feild, J., Chaikin, M., Kline, T., Watt, R., Poste, G., Greig, R. (1987) Oncogene expression in primary and metastatic human-colon carcinoma. *Gastroenterology*, 92(5) 1673.
177. Clark, R.K., Bailey, D.S., Bryant, S.L., Trainer, D.L., Poste, G., Greig, R. (1987) Differentiation and carbohydrate expression in colon-carcinoma. *Proceedings of the American Association of Cancer Research*. March, Vol. 28, 39.
178. Bailey, D.S., Kline, T., Clark, R.K., Hoffstein, S., Poste, G., Greig, R. (1987) Glycoprotein synthesis by Human Colon Carcinoma Cells In Vitro and As Xenografts in Nude Mice. *Biochem. Soc. Trans.*, 15(3), 385.
179. Griswold, D.G., Webb, E.F., Godfrey, R., DiMartino, M.J., Sarau, H., Poste, G. and Hanna, N. (1987) SK&F 86002: A novel anti-inflammatory agent producing inhibition of lipooxygenase- and cyclooxygenase-mediated arachidonic acid metabolism. *Biochem. Pharmacol.* 36, 3463-3470.
180. Kirsh, R., Poste, G. (1987) Liposome-Mediated Macrophage Activities. *Methods in Enzymology* 149, 147-157.
181. Poste, G. and Crooke, S.T. (1987) Editors. *New Frontiers in the Study of Gene Functions*. *New Horizons in Therapeutics*, Plenum Press, New York.
182. Poste, G. (1987) Industrial biotechnology in Europe-Issues for public policy. *A Book Review The Scientist* 1, 23.
183. Koestler, T., Johnson, W., Rieman, D., Dalton, B., Greig, R., and Poste, G. (1987) Differential expression of murine macrophage-mediated tumor cytotoxicity induced by interferons. *Cancer Research* 47, 2804-2808.
184. Niewiarowska, A., Caltabiano, M.M., Bailey, D.S., Poste, G., and Greig, R.G. (1987) Alterations in lipid-linked oligosaccharide metabolism in human melanoma cells concomitant with induction of stress proteins. *J. Biol. Chem.* 262, 14815-14820.
185. Bugelski, P.J., Corwin, S.P., North, S.M., Kirsh, R.L., Nicolson, G.L. and Poste, G. (1987) Macrophage content of spontaneous metastases at different stages of growth. *Cancer Research* 47, 4141-4145.
186. Bugelski, P.J., Kirsh, R., Buscarino, C., Corwin, S.P. and Poste, G. (1987) Recruitment of exogenous macrophages into metastases at different stages of tumor growth. *Cancer Immunol. Immunotherap.* 24, 93-98.
187. Dunnington, D.J., Buscarino, C., Gennaro, D., Greig, R., and Poste, G. (1987) Characterization of an animal model of metastatic colon carcinoma. *Int. J. Cancer* 39, 248-254.
188. Rees, R., Dalton, B., Young, J., Hanna, N., and Poste, G. (1987) Augmentation of human natural killer cell activity by influenza virus antigens produced in *E. Coli*. *J. Biol. Res. Mod.*, 6, 9-87.
189. Lester, B.R., Stadel, J.M., Buscarino, C., Sheppard, J., Greig, R.G., and Poste, G. (1987) Reconstitution of the Gs protein from B16 melanoma clones of high and low experimental metastatic potential into S49 CYC membranes. *Biochemical and Biophysical Research Communications* 147, 443-451.
190. DiMartino, M.J., Griswold, D.E., Berkowitz, B.A., Poste, G., and Hanna, N. (1987) Pharmacologic characterization of the antiinflammatory properties of a new dual inhibitor of lipooxygenase and cyclooxygenase. *Agents and Actions* Vol. 20, 113- 123.

191. Wright, B., Zeidman, I., Greig, R., Poste, G. (1986) Calcium fluxes and calmodulin inhibitors in macrophage activation. *Cellular Immunology*, 100(2), 586-587.
192. Caltabiano, M.M., Koestler, T.P., Poste, G., Greig, R.G. (1986) Compound used in the therapy of rheumatoid-arthritis. *Biochemical and Biophysical Research Communications*, 138(3) 1074-1080.
193. Poste, G., Greig, R. (1986) The Cell-Surface and Cancer Metastasis. *American Zoologist*, 26(3), 567.
194. Greig, Russell G., and Poste, G. (1986) Biological Membranes and Malignancy: An Overview of Pharmacological Opportunities. In: *Annals of the New York Academy of Sciences*, Vol. 488.
195. Kirsh, R., and Poste, G. (1986) Liposome targeting to macrophages: opportunities for treatment of infectious diseases. In: *Infections in the Immunocompromised Host-Laboratory Diagnosis and Treatment*. Eds. P. Actor, A. Evangelista, J. Poupard and E. Hinks, Plenum Press, New York. pp 171-184.
196. Kirsh, R., and Poste, G. (1986) Liposome targeting to macrophages: opportunities for treatment of infectious diseases. In: *Infections in the Immunocompromised Host-Laboratory Diagnosis and Treatment*. Eds. P. Actor, A. Evangelista, J. Poupard and E. Hinks, Plenum Press, New York. pp 171-184.
197. Gregoriadis, G., Senior, J., and Poste, G. (1986) Editors. Targeting of drugs with synthetic systems. NATO ASI Series. Plenum Press, New York, Vol. 113.
198. Kirsh, R. and Poste, G. (1986) Liposome mediated drug delivery to mononuclear phagocytes in vivo: Applications in antimicrobial therapy. In: *Medical Applications of Liposomes*. (ed. K. Yagi) pp. 99-104 Karger, Basel.
199. Horan, P.K., Slezak, D. and Poste, G. (1986) Improved flow cytometric analysis of leukocyte cell subsets: Simultaneous identification of five cell subsets using two color immunofluorescence. *Proc. Nat. Acad. Sci. USA*, 82, 8361-8365.
200. Lester, B. R., Greig, R. G., Buscarino, C. Sheppard, J. R., Corwin, S. P. and Poste, G. (1986) cAMP metabolism in B16 Melanoma clones during the formation of experimental and spontaneous metastases. *Int. J. Cancer* 38, 405-411.
201. S. Steinberg) Plenum Publishing Corp.
202. Poste, G., and Greig, R. (1986) The Cell Surface and Cancer Metastasis. *Developmental Biology Volume 3*, 15-31 (ed. M.
203. Van Alstine, J.M., Sorensen, P., Webber, T.J., Greig, R., Poste, G. and Brooks, D.E. (1986) Heterogeneity in the surface properties of B16 melanoma cells from sublines with differing metastatic potential detected via two polymer aqueous phase partition. *Experimental Cell Research* 164, 366-378.
204. Caltabiano, M., Koestler, T., Poste, G. and Greig, R. (1986) Induction of 32- and 34-kDa stress proteins by sodium arsenite, heavy metals, and thiol-reactive agents. *J. Biol. Chem.* 261, 13381-13386.
205. Caltabiano, M. M., Koestler, T. P., Poste, G. and Greig, R. (1986) Induction of mammalian stress proteins by triethylphosphine gold compound used in the therapy of rheumatoid arthritis. *Biochem. Biophys. Res. Comm.* 138, 1074- 1080.
206. Poste, G. (1986). Cell surface alterations and the metastatic behavior of tumor cells. In: *Interaction of Cells with Natural and Foreign Surfaces*. (ed. N. Crawford) Plenum Press, New York.
207. Kirsh, R. and Poste, G. (1986) Macrophage-mediated tumor cell destruction: opportunities for treatment of metastatic disease. In: *Receptors in Tumor Biology*. (ed. C. M. Chadwick) Marcel Dekker, New York.
208. Poste, G. and Crooke, S.T. (1986) Editors. New insights into cell and membrane transport processes. *New Horizons in Therapeutics*. Vol. 3. Plenum Press, New York.
209. Sheppard, J. R., Lester, B., Doll, J., Buscarino, C., Gonzales, E., Corwin, S., Greig, R. and Poste G. (1986) Biochemical regulation of adenylate cyclase in murine melanoma clones with different metastatic properties. *Int. J. Cancer* 37, 713-722.
210. Nicolson, G.L., Fidler, I.J. and Poste, G. (1986) The effects of tertiary amine local anesthetics on the blood-borne implantation and cell surface properties of metastatic mouse melanoma cells. *J. Nat. Cancer Inst.* 76, 511-519.
211. Lee, J., Rebar, L., Young, P., Ruscetti, F., Hanna, N. and Poste, G. (1986) Identification and characterization of a human T cell line-derived lymphokine with MAF-like activity distinct from gamma interferon. *J. Immunol.* 136, 1322-1328.
212. Poste, G. (1986) Pathogenesis of metastatic disease: Implications for current therapy and for the development of new therapeutic strategies. *Cancer Treatment Reports.* 70, 183-199.
213. Poste, G. and Greig, R. (1986) Experimental Models for Studying the Pathogenesis and Therapy of Metastatic Disease. In: *Mechanisms of Cancer Metastasis: Potential therapeutic implications*. (ed. K. V. Honn) pp. 41-68 Martinus Nijhoff, Boston.
214. Poste, G. and Crooke, S.T. (1985) Editors. *Mechanisms of Receptor Regulation*. New Horizons in Therapeutics, Vol. 2. Plenum Press, New York.
215. *Colloids and Surfaces* 14, 339-348
216. Kirsh, R. and Poste, G. (1985) Liposome mediated delivery of biological response modifiers (BRM) to macrophages in vivo: A new strategy for therapy of neoplastic disease.
217. Poste, G. (1985) The pharmaceutical industry and health care in the third world. *Biotechnology* 3, 704-706.
218. Griswold, D.E., Antell, L., Bender, P.E., Hanna, N. and Poste, G. (1985) Induction of suppressor cells, interleukin 2 production and

- mitogenesis with monomeric concanavalin A: different actions of tetrameric and monomeric concanavalin A. *Mol. Immunol.* 22, 1311-1316.
219. Muirhead, K., Bender, P., Hanna, N. and Poste, G. (1985) Binding of histamine and histamine analogs to lymphocyte subsets analyzed by flow cytometry. *J. Immunol.* 135, 4120-4128.
220. Greig, R.G., Caltabiano, L., Feild, J., Reid, Jr., R. and Poste, G. (1985) Alterations in the phosphoprotein composition of tumor cell clones induced by cell culture techniques used routinely in assessing metastatic behavior in vivo. *Int. J. Cancer* 35, 367-375.
221. Koestler, T., Badger, A., Rieman, D., Greig, R. and Poste, G. (1985) Induction by immunomodulatory agents of a macrophage antigen recognized by monoclonal antibody 158.2 and correlation with macrophage function. *Cellular Immunology* 96, 113-125.
222. Wright, B., Zeidman, I., Greig, R. and Poste, G. (1985) Inhibition of macrophage activation by calcium channel blockers and calmodulin antagonists. *Cellular Immunology* 95, 46-53.
223. Poste, G. (1985) Current concepts of cancer metastasis. *Transactions and Studies of the College of Physicians of Philadelphia series* 5, 7, 239-252.
224. Trainer, D., Kline, T., Mallon, F., Greig, R. and Poste, G. (1985) Effect of 5-azacytidine on DNA methylation and the malignant properties of B16 melanoma cells. *Cancer Research* 45, 6124-6130.
225. Fidler, I.J. and Poste, G. (1985) The cellular heterogeneity of malignant neoplasms: Implications for adjuvant chemotherapy. *Seminars in Oncology*, 12, 207-221.
226. Greig, R.G., Koestler, T.P., Trainer, D.L., Corwin, S., Miles, L., Kline, T., Sweet, R., Yokoyama, S. and Poste, G. (1985) Tumorigenic and metastatic properties of "normal" and ras-transfected NIH/3T3 cells. *Proc. Nat. Acad. Sci., USA* 82, 3698-3701.
227. Ferguson, B., Pritchard, L., Feild, J., Reiman, D., Greig, R., Poste, G. and Rosenberg, M. (1985) Isolation analysis of an Abelson murine leukemia virus-encoded tyrosine-specific kinase produced in *E. coli*. *J. Biol. Chem.* 260, 3652-3657.
228. Bugelski, P.J., Kirsh, R., Corwin, S., Sowinski, J. and Poste, G. (1985) Changes in the macrophage content of lung metastases at different stages in tumor growth. *Am. J. Pathol.* 118, 419-424.
229. Ravetch, J.V., Young, J. and Poste, G. (1985) Molecular Genetic Strategies for the Development of Anti-Malarial Vaccines. *Biotechnology* 3, 729-740.
230. Poste, G. (1985) Drug Targeting in Cancer Therapy. In: *Receptor-Mediated Targeting of Drugs*. (eds. G. Gregoriadis, J. Senior, G. Poste and A. Trouet) pp. 427-474. Plenum Press, New York.
231. Greig, R.G., Lester, B., Sorensen, P., Buscarino, C. and Poste, G. (1985) Hormonal regulation of B16 melanoma metastasis. In: *Treatment of Metastasis: Problems and Prospects*. (eds. K. Hellmann and S.A. Eccles.) pp. 121-124. Taylor and Francis, London.
232. Muirhead, K.A., Horan, P.K. and Poste, G. (1985) Flow Cytometry: Present and future. *Biotechnology* 3, 337-356.
233. Griswold, Don E., Lee, J. C., Poste, G. and Hanna, N. (1985) Modulation of macrophage-lymphocyte interactions by the antiarthritic gold compound, auranofin. *J. Rheumatol.* 12, 490-497.
234. Poste, G. (1985) Tumor cell heterogeneity and the pathogenesis of cancer metastasis. In: *Basic Mechanisms and Clinical Treatment of Tumor Metastasis*. (eds. Torisu, M and Yoshida, T.) pp. 79-100. Academic Press, New York.
235. Poste, G., (1984) The mystery of metastasis: What we know, so far. *Your Patient and Cancer* April, 59-61.
236. Koestler, T.P., Kirsh, R., Kline, T., Rieman, D., Greig, R. and Poste, G. (1984) Production of C3 as a marker of lymphokine-mediated macrophage activation. *Cell. Immunol.* 87, 1-14.
237. Koestler, T.P., Rieman, D., Muirhead, K., Greig, R.G. and Poste, G. (1984) Identification and characterization of a monoclonal antibody to an antigen expressed on activated macrophages (lymphokine/hybridoma/cell surface antigens/immunofluorescence/macrophage-mediated cytotoxicity. *Proc. Nat. cad. Sci. USA.* 81, 4505-4509.
238. Poste, G. (1984) New insights into receptor regulation. *J. Applied Physiol.* 57, 1297-1305.
239. Kirsh, R. and Poste, G. (1984) Liposomes and targeted drug delivery to macrophages: A potential system for improved therapy of microbial infections. *Clin. Immunol. Newsletter* 5, 168-171.
240. Poste, G. (1984) Hype, Hope and Honesty: Reporting of Cancer Discoveries by the Media. *Biotechnology* 2, 1096.
241. Poste, G., Kirsh, R. and Bugelski, P. (1984) Liposomes as a drug delivery system in cancer therapy. In: *Novel Approaches to Cancer Chemotherapy*. (ed. P. Sunkara) pp. 165-230. Academic Press, New York.
242. Poste, G. and Crooke, S.T. (1984) Editors. *Dopamine Receptor Agonists*. *New Horizons in Therapeutics*. Vol. 1. Plenum Press, New York.
243. Poste, G. (1984) Liposomes: fascination, frustration, feasibility and fantasy. In: *Liposome Letters*. (ed. A.D. Bangham) pp. 375-386. Academic Press, London.
244. Poste, G. and Nicolson, G.L. (1984) In vitro systems for studying the interaction of metastatic tumor cells with endothelial cells and subendothelial basement membranes. In: *Biology of Endothelial Cells*. (ed. E. A. Jaffe) pp. 438-448. Martinus Nijhoff, Boston.
245. Poste, G., Tzeng, J., Koestler, T., Corwin, S., and Greig, R. (1984) Interactions between tumor cell subpopulations in malignant tumors. In: *Cancer Invasion and Metastasis: Biological and Therapeutic Aspects*. (eds. G. Nicolson and L. Milas) pp. 223-244.

Raven Press, New York.

246. Kirsh, R. and Poste, G. (1984) Macrophage activation in vivo: New approaches to the therapy of metastatic tumors. *EOS J. Immunol. Immunopharmacol.* IV, 32-35.
247. Griswold, D.E., Alessi, S., Badger, A.M., Poste, G. and Hanna, N. (1984) Inhibition of T suppressor cell expression by histamine type 2 (H₂) receptor antagonists. *J. Immunol.* 132, 3054-3057.
248. Sheppard, J.R., Koestler, T., Corwin, S., Buscarino, C., Doll, J., Lester, B., Greig, R. and Poste, G. (1984) Experimental metastasis correlates with cyclic AMP accumulation in B16 melanoma clones. *Nature* 308, 544-547.
249. Kirsh, R. and Poste, G. (1984) Liposome encapsulation of biological response modifiers: Activation of tumoricidal macrophages. In: *Liposome Technology* (ed. G. Gregoriadis) Vol. 2, pp. 33-53. CRC Press, Boca Raton, Florida.
250. Poste, G., Kirsh, R. and Koestler, T. (1984) The challenge of liposome targeting in vivo. In: *Liposome Technology* (ed. G. Gregoriadis) Vol. 3, pp. 1-28. CRC Press, Boca Raton, Florida.
251. Poste, G. and Greig, R. (1983) The experimental and clinical implications of cellular heterogeneity in malignant tumors. *J. Cancer Res. Clin. Oncol.* 106, 159-170.
252. Nicolson, G.L. and Poste, G. (1983) Tumor implantation and invasion at metastatic sites. *Int. Rev. Exp. Pathol.* 25, 77-181.
253. Poste, G. (1983) Whatever happened to the industry I was told to distrust. *Immunology Today* 4, 133-136.
254. Kirsh, R. and Poste, G. (1983) Stimulation of host resistance to metastatic tumors by macrophage activating agents encapsulated in liposomes. In: *Host Defenses to Intracellular Pathogens*. (ed. T.K. Eisenstein) *Adv. Exp. Biol. Med.* Vol. 162, pp. 69-75. Raven Press, New York.
255. Nicolson, G.L. and Poste, G. (1983) Tumor cell diversity and host responses in cancer metastasis. II. Host immune responses and therapy of metastases. In: *Current Problems in Cancer*. (ed. R.C. Hickey) Vol. 7, pp. 1-42. Yearbook Medical Publishers, Chicago.
256. Poste, G. (1983) Liposome targeting in vivo: problems and opportunities. In: *Liposomes in Vivo*. (eds. C. Nicolau and G. Poste). *Biol. Cell.* 47, pp. 19-38.
257. Poste, G. and Nicolson, G.L. (1983) Experimental systems for analysis of the surface properties of metastatic tumor cells. In: *Biomembranes*. (ed. A. Nowotny) Vol. 11, pp. 341-364. Plenum Press, New York.
258. Poste, G. and Kirsh, R. (1983) Site-specific (targeted) drug delivery in cancer therapy. *Biotechnology* 1, 869-878.
259. Hanna, N., DiMartino, M., Griswold, D.E. and Poste, G. (1983) Immunology of auranofin. *Current Clinical Practice* 7, 60-70.
260. Griswold, D.E., Badger, A.M., Bender, P.E., Sitrin, R.D., Antell, L., Greig, R.G. and Poste, G. (1983) Differential effects of intact subunits and nicked fragments of concanavalin A on immune functions in vitro and in vivo. *J. Immunol.* 131, 1626-1628.
261. Badger, A., Brown, A.E. and Poste, G. (1983) The effect of cimetidine on antibody synthesis in vitro and in vivo. *Immunology* 48, 151-155.
262. Badger, A., Young, J. and Poste, G. (1983) Inhibition of phytohaemagglutinin-induced proliferation of human peripheral blood lymphocytes by histamine and histamine H₁ and H₂ agonists. *Clin. Exp. Immunol.* 51, 178-184.
263. Bugelski, P.J., Kirsh, R.L. and Poste, G. (1983) New histochemical method for measuring intratumoral macrophages and macrophage recruitment into experimental metastases. *Cancer Research* 43, 5493-5501.
264. Greig, R. G., Caltabiano, L., Reid, Jr., R., Feild, J. and Poste, G. (1983) Heterogeneity of protein phosphorylation in metastatic variants of B16 melanoma. *Cancer Research* 43, 6057-6065.
265. Poste, G. (1983) Tumor cell heterogeneity and the metastatic process. In: *Understanding Breast Cancer: Clinical and Laboratory Concepts*. (eds. M.A. Rich, J.C. Hager and P. Furmanski) pp. 119-143. Marcel Dekker, Inc., New York.
266. Poste, G. and Nicolson, G.L. (1982) Editors. *Cell Surface Reviews, Volume 8. Membrane Reconstitution*. Elsevier/North-Holland, Amsterdam. 360 pages.
267. Poste, G., Bucana, C. and Fidler, I.J. (1982) Stimulation of host response against metastatic tumors by liposome-encapsulated immunomodulators. In: *Targeting of Drugs*. (eds. G. Gregoriadis, J. Senior and A. Trouet) NATO Advanced Studies Institute Series, Vol. A47, pp. 261-284. Plenum Press, New York.
268. Poste, G. and Kirsh, R. (1982) Liposome-encapsulated macrophage activation agents and active non-specific immunotherapy of neoplastic disease. In: *Cell Function and Differentiation, Part A*. (ed. A. Evangelopoulos) pp. 309-319. Alan R. Liss, New York.
269. Fidler, I.J. and Poste, G. (1982) The heterogeneity of metastatic properties in malignant tumor cells and regulation of the metastatic phenotype. In: *Tumor Cell Heterogeneity: Origins and Implications*. (eds. A. Owens, Coffey, D. S., and S. Balin) pp. 127-145. Academic Press, New York.
270. I.J. Fidler) Vol. 1, pp. 141-199. Martinus Nijhoff, Amsterdam.
271. Poste, G. (1982) Experimental systems for analysis of the malignant phenotype. In: *Cancer and Metastasis Reviews*. (ed. ...)
272. Fidler, I.J. and Poste, G. (1982) Macrophages and Cancer Metastasis. In: *Macrophages and Natural Killer Cells. Advances in Experimental Medicine and Biology*, Vol. 155. (eds. S.J. Normann and E. Sorkin) pp. 65-75. Plenum Press, New York.

273. Nicolson, G.L. and Poste, G. (1982) Tumor cell diversity and host responses in cancer metastasis. I. Properties of metastatic cells. In: *Current Problems in Cancer*. (ed. R.C. Hickey) pp. 1-83. Yearbook Medical Publishers, Chicago.
274. Poste, G. (1982) Variation in the metastatic properties of cells from malignant tumors and the control of the metastatic phenotype. In: *Tumour Progression and Markers*. (ed. M. Price) pp. 197-210. Kugler Publications, Amsterdam.
275. Poste, G. (1982) Liposomes as a carrier system for improved delivery of biologically-active materials to cells in vitro and In vivo. In: *Liposome Methodology*. (eds. L.D. Leserman and J. Barbet) pp. 65-77. Inserm, Paris.
276. Brown, A.E., Badger, A.M. and Poste, G. (1982) The effect of cimetidine on immune cell function and host response to tumors. In: *Current Concepts in Human Immunology and Cancer Immunomodulation*. (ed. B. Serrou) pp. 513-519. Elsevier, Amsterdam.
277. Poste, G. (1982) Methods and models for studying tumor invasion. In: *Tumor Invasion and Metastasis*. (eds. L.A. Liotta and I.R. Hart) pp. 147-171. Martinus Nijhoff, Amsterdam.
278. Poste, G. and Fidler, I.J. (1982) Therapeutic amplification of macrophage-mediated destruction of tumor cells: An approach to cancer therapy that addresses the problem of tumor cell heterogeneity. In: *Design of Models for Testing Cancer Therapeutic Agents*. (eds. I.J. Fidler and R.J. White) pp. 225-238. Van Nostrand, New York.
279. Poste, G. and Fidler, I.J. (1982) Active non-specific immunotherapy of lung metastases by macrophages activating agents encapsulated in liposomes. In: *Optimization of Drug Delivery, Alfred Benzon Symposium 17*. (eds. H. Bundgaard, A. Bagger Hansen and H. Kofod) pp. 418-431. Munksgaard, Copenhagen.
280. Poste, G. (1982) Cellular heterogeneity in malignant neoplasms and the therapy of metastases. *Ann. N.Y. Acad. Sci.* 391, 34-48.
281. Sitrin, R.D., Antell, L.A., Griswold, D.E., Bender, P.E., Greig, R.G. and Poste, G. (1982) A high performance liquid chromatography assay for the rapid analysis of the subunit content of concanavalin A. *Biochim. Biophys. Acta* 717 (1) 175- 178.
282. Badger, A., Griswold, D.E., DiMartino, M.J. and Poste, G. (1982) Inhibition of antibody synthesis by histamine in concanavalin A-treated mice: The possible role of glucocorticosteroids. *J. Immunol.* 129, 1017-1022.
283. Poste, G., Tzeng, J., Doll, J., Greig, R., Rieman, D. and Zeidman, I. (1982) Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases. *Proc. Nat. Acad. Sci. USA* 79, 6574-6578.
284. Fidler, I.J. and Poste, G. (1982) Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. *Springer Semin. Immunopathol.* 5, 161-174.
285. Poste, G. and Greig, R. (1982) On the genesis and regulation of cellular heterogeneity in malignant tumors. *Invasion and Metastasis* 2, 137-176.
286. Poste, G., Doll, J., Brown, A.E., Tzeng, J. and Zeidman, I. (1982) Comparison of the metastatic properties of B16 melanoma clones isolated from cultured cell lines, Cancer Research 42, 1412-1422. subcutaneous tumors, and individual lung metastases. *Cancer Research* 42, 2770- 2778.
287. Poste, G., Bucana, C., Raz, A., Bugelski, P., Kirsh, R. and Fidler, I.J. (1982) Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery.
288. Poste, G. and Flood, M.K. (1981) Cells transformed by temperature-sensitive mutants of avian sarcoma virus cause tumors in vivo at both permissive and nonpermissive temperatures. In: *Readings in Mammalian Cell Culture*. (ed. R. Pollack) pp. 351-362. Cold Spring Harbor Laboratory, New York.
289. G.P. Murphy, A.A. Sandberg and J.P. Karr) Part B, pp. 257-267. Alan R. Liss, New York. sulated within liposomes as a treatment for spontaneous metastasis. In: *The Prostatic Cell: Structure and Function*. (eds.
290. Fidler, I.J. and Poste, G. (1981) Activation of tumoricidal properties in murine macrophages by intravenous injection of muramyl dipeptide encap-
291. Fidler, I.J. and Poste, G. (1981) Treatment of spontaneous murine metas-tases by the systemic administration of liposomes containing macrophage-activating agents. In: *Cancer: Achievements, Challenges and Prospects for the 1980s*. (eds J.H. Burchemall and H.F. Oettgen) Vol. 2, pp. 77-89. Grune and Stratton, New York.
292. Poste, G. and Fidler, I.J. (1981) Stimulation of macrophage-mediated destruction of lung metastases by administration of immunomodulators encapsulated in liposomes. In: *Liposomes, Drugs and Immunocompetent Cell Functions*. (eds. C. Nicolau and A. Paraf) pp. 147-161. Academic Press, New York.
293. In: *Manual of Macrophage Methodology*. (eds. H.B. Herscowitz, H.T. Holden, J.A. Bellanti and A. Ghaffar) pp. 509-514. Marcel Dekker, New York.
294. Fidler, I.J. and Poste, G. (1981) Macrophage destruction of micrometastases.
295. Poste, G. and Fidler, I.J. (1981) Activation of macrophages by lymphocyte mediators encapsulated in liposomes. In: *Manual of Macrophage Methodology*. (eds. H.B. Herscowitz, H.T. Holden, J.A. Bellanti and A. Ghaffar) pp. 431-438. Marcel Dekker, New York.
296. Poste, G., Doll, J. and Fidler, I.J. (1981) Interactions among clonal subpopulations affect the stability of the metastatic phenotype in poly-clonal populations of B16 melanoma cells. *Proc. Nat. Acad. Sci. USA* 78, 6226-6230.
297. Hart, I.R., Fogler, W.E., Poste, G. and Fidler, I.J. (1981) Toxicity studies of liposome-encapsulated immunomodulators administered

- intravenously to dogs and mice. *Cancer Immunol. Immunother.* 10, 157-166.
298. Fidler, I.J., Raz, A., Fogler, W.E., Hoyer, L.C. and Poste, G. (1981) The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes. *Cancer Research* 41, 495-504.
299. Raz, A., Bucana, C., Fogler, W.E., Poste, G. and Fidler, I.J. Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. *Cancer Research* 41, 487-494.
300. Cotman, C., Poste, G. and Nicolson, G.L. (1980) Editors. *Cell Surface Reviews, Volume 6. The Cell Surface and Neuronal Function.* Elsevier/North-Holland, Amsterdam. 546 pp.
301. Fidler, I.J., Barnes, Z., Fogler, W.E., Kirsh, R., Bugelski, P. and Poste, G. (1982) Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. *Cancer Research* 42, 496-501.
302. Fidler, I.J. and Poste, G. (1982) The biologic diversity of cancer metastases. *Hospital Practice* 17, 57-64.
303. Poste, G. and Nicolson, G.L. (1981) Editors. *Cell Surface Reviews, Volume 7. Cytoskeletal Elements and Plasma Membrane Organization.* Elsevier/North-Holland, Amsterdam. 349 pp.
304. Poste, G. and Flood, M.K. (1981) Cells transformed by temperature-sensitive mutants of avian sarcoma virus cause tumors in vivo at both permissive and nonpermissive temperatures. In: *Readings in Mammalian Cell Culture.* (ed. R. Pollack) pp. 351-362. Cold Spring Harbor Laboratory, New York.
305. Fidler, I.J. and Poste, G. (1981) Activation of tumoricidal properties in murine macrophages by intravenous injection of muramyl dipeptide encapsulated within liposomes as a treatment for spontaneous metastasis. In: *The Prostatic Cell: Structure and Function.* (eds. G.P. Murphy, A.A. Sandberg and J.P. Karr) Part B, pp. 257-267. Alan R. Liss, New York.
306. Fidler, I.J. and Poste, G. (1981) Treatment of spontaneous murine metastases by the systemic administration of liposomes containing macrophage-activating agents. In: *Cancer: Achievements, Challenges and Prospects for the 1980s.* (eds J.H. Burchemall and H.F. Oettgen) Vol. 2, pp. 77-89. Grune and Stratton, New York.
307. Poste, G. and Fidler, I.J. (1981) Stimulation of macrophage-mediated destruction of lung metastases by administration of immunomodulators encapsulated in liposomes. In: *Liposomes, Drugs and Immunocompetent Cell Functions.* (eds. C. Nicolau and A. Paraf) pp. 147-161. Academic Press, New York.
308. In: *Manual of Macrophage Methodology.* (eds. H.B. Herscovitz, H.T. Holden, J.A. Bellanti and A. Ghaffar) pp. 509-514. Marcel Dekker, New York.
309. Fidler, I.J. and Poste, G. (1981) Macrophage destruction of micrometastases.
310. Poste, G. and Fidler, I.J. (1981) Activation of macrophages by lymphocyte mediators encapsulated in liposomes. In: *Manual of Macrophage Methodology.* (eds. H.B. Herscovitz, H.T. Holden, J.A. Bellanti and A. Ghaffar) pp. 431-438. Marcel Dekker, New York.
311. Poste, G., Doll, J. and Fidler, I.J. (1981) Interactions among clonal subpopulations affect the stability of the metastatic phenotype in poly-clonal populations of B16 melanoma cells. *Proc. Nat. Acad. Sci. USA* 78, 6226-6230.
312. Hart, I.R., Fogler, W.E., Poste, G. and Fidler, I.J. (1981) Toxicity studies of liposome-encapsulated immunomodulators administered intravenously to dogs and mice. *Cancer Immunol. Immunother.* 10, 157-166.
313. Fidler, I. J., Raz, A., Fogler, W. E., Hoyer, L.C. and Poste, G. (1981) The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes. *Cancer Research* 41, 495-504.
314. Raz, A., Bucana, C., Fogler, W. E., Poste, G. and Fidler, I. J. Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. *Cancer Research* 41, 487-494.
315. Cotman, C., Poste, G. and Nicolson, G.L. (1980) Editors. *Cell Surface Reviews, Volume 6. The Cell Surface and Neuronal Function.* Elsevier/North-Holland, Amsterdam. 546 pp.
316. Fidler, I. J., Hart, I. R., Raz, A., Fogler, W. E., Kirsh, R. and Poste, G. (1980) Activation of tumoricidal properties in macrophages by liposome-encapsulated lymphokines: In vivo studies. In: *Liposomes and Immunobiology.* (eds. B. Tom and H. Six) pp. 109-118. Elsevier/North-Holland, Amsterdam.
317. Fidler, I. J., Raz, A., Fogler, W. E. and Poste, G. (1980) Pulmonary localization of intravenously injected liposomes. In: *Recent Results in Cancer Research.* (eds. G. Mathe and F.M. Muggia) Vol. 75, pp. 246-251. Springer Verlag, Berlin.
318. Poste, G., Kirsh, R., Raz, A., Sone, S., Bucana, C., Fogler, W.E. and Fidler, I.J. (1980) Activation of tumoricidal properties in macrophages by liposome-encapsulated lymphokines: In vitro studies. In: *Liposomes and Immunobiology.* (eds. B. Tom and H. Six) pp. 93-107. Elsevier/North-Holland, Amsterdam.
319. Poste, G. (1980) The influence of cell surface properties on the arrest of circulating melanoma cells. In: *Tumor Cell Surfaces and Malignancy.* (eds. R.O. Hynes and C.F. Fox) pp. 737-745. Alan R. Liss, New York.
320. Poste, G. (1980) The interaction of lipid vesicles (liposomes) with cultured cells and their use as carriers for drugs and macromolecules. In: *Liposomes in Biological Systems.* (eds. G. Gregoriadis and A.C. Allison) pp. 101-151. J. Wiley, New York.
321. Poste, G. (1980) Surface molecules and tumour-cell metastatic properties. *Biochem. Soc. Trans.* 8, 695-697.

322. the plasma membrane of cultured cells. *Exp. Cell Research* 129, 393-408.
323. Poste, G., Lyon, N.C., Macander, P., Porter, C.W., Reeve, P. and Bachmeyer, H. (1980) Liposome-mediated transfer of integral membrane glycoproteins into
324. Fidler, I.J., Raz, A., Fogler, W.E., Kirsh, R., Bugelski, P. and Poste, G. (1980) Design of liposomes to improve delivery of macrophage augmenting agents to alveolar macrophages. *Cancer Research* 40, 4460-4466.
325. Poste, G., Doll, J., Hart, I.R. and Fidler, I.J. (1980) In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. *Cancer Research* 40, 1636-1644.
326. Sone, S., Poste, G. and Fidler, I.J. (1980) Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines. *J. Immunol.* 124, 2197-2202.
327. Poste, G. and Fidler, I.J. (1980) The pathogenesis of cancer metastasis. *Nature* 283, 139-146.
328. Poste, G. and Nicolson, G.L. (1980) Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells. *Proc. Nat. Acad. Sci. USA* 77, 399-403.
329. Papahadjopoulos, D., Poste, G. and Vail, W.J. (1979) Studies on membrane fusion with natural and model membranes. In: *Methods in Membrane Biology*. (ed. E. Korn) pp. 1-121. Plenum Press, New York.
330. Poste, G. (1979) The surface properties of invasive and metastatic tumour-cell populations. *British J. Cancer* 39, 467-469.
331. Poste, G. (1979) The tumoricidal properties of inflammatory tissue macrophages and multinucleate giant cells. *Am. J. Pathol.* 96, 595-608.
332. Nicolson, G.L. and Poste, G. (1979) Lectin-mediated agglutination of murine lymphoma cells: cell surface deformability and reversibility of agglutination by saccharides. *Biochim. Biophys. Acta* 554, 520-531.
333. Poste, G. and Flood, M.K. (1979) Cells transformed by temperature-sensitive mutants of avian sarcoma virus cause tumors in vivo at both permissive and nonpermissive temperatures. *Cell* 17, 789-800.
334. Poste, G. and Kirsh, R. (1979) Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages. *Cancer Research* 39, 2582-2590.
335. Poste, G., Kirsh, R., Fogler, W. and Fidler, I.J. (1979) Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. *Cancer Research* 39, 881-892.
336. Poste, G., Allen, H. and Matta, K.L. (1979) Cell surface receptors for lymphokines. II. Studies on the carbohydrate composition of the MIF receptor on macrophages using synthetic saccharides and plant lectins. *Cell. Immunol.* 44, 89-98.
337. Poste, G., Kirsh, R. and Fidler, I.J. (1979) Cell surface receptors for lymphokines. I. The possible role of glycolipids as receptors for macrophage migration inhibitory factor (MIF) and macrophage activation factor (MAF). *Cell. Immunol.* 44, 71-88.
338. Poste, G. and Nicolson, G.L. (1978) Editors. *Cell Surface Reviews*, Volume 5. Membrane Fusion. Elsevier/North-Holland, Amsterdam. 862 pages.
339. Poste, G., Reeve, P. and Bachmeyer, H. (1978) Interaction of lipid vesicles containing paramyxovirus envelope glycoproteins with cultured cells. In: *Negative Strand Viruses and the Host Cell*. (eds. B.W.J. Mahy and R.D. Barry) pp. 815-823. Academic Press, New York.
340. Poste, G. and Lyon, N. (1978) Enucleation of cultured animal cells by cytochalasin B. In: *Cytochalasins - Biochemical and Cell Biological Aspects*. (ed. S. Tanenbaum) pp. 161-189. Elsevier/North-Holland, Amsterdam.
341. Poste, G. and Pasternak, C.A. (1978) Virus-induced cell fusion. In: *Membrane Fusion*. (eds. G. Poste and G.L. Nicolson) *Cell Surface Reviews*, Vol. 5, pp. 305-367. Elsevier/North-Holland, Amsterdam.
342. Poste, G. and Papahadjopoulos, D. (1978) The influence of vesicle membrane properties on the interaction of lipid vesicles with cultured cells. *Ann. N.Y. Acad. Sci.* 308, 164-184.
343. Nicolson, G.L. and Poste, G. (1978) Mechanism of resistance to ricin toxin in selected mouse lymphoma cell lines. *J. Supramolec. Structure* 8, 235-245. *Biochim. Biophys. Acta* 510, 256-263.
344. Poste, G., Porter, C.W. and Papahadjopoulos, D. (1978) Identification of a potential artifact in the use of electron microscope autoradiography to localize saturated phospholipids in cells. *Cell. Immunol.* 38, 131-146.
345. Fidler, I.J., Roblin, R.O. and Poste, G. (1978) In vitro tumoricidal activity of macrophages against virus-transformed lines with temperature-dependent transformed phenotypic characteristics.
346. Poste, G. and Nicolson, G.L. (1977) Editors. *Cell Surface Reviews*, Volume 4. The Synthesis, Assembly and Turnover of Cell Surface Components. Elsevier/North-Holland, Amsterdam. 883 pages.
347. Poste, G. and Nicolson, G.L. (1977) Editors. *Cell Surface Reviews*, Volume 3. Dynamic Aspects of Cell Surface Organization. Elsevier/North-Holland, Amsterdam. 750 pages.
348. Poste, G. and Nicolson, G.L. (1977) Editors. *Cell Surface Reviews*, Volume 2. Virus Infection and the Cell Surface. Elsevier/North-Holland, Amsterdam. 350 pages.
349. Nicolson, G.L., Poste, G. and Ji, J.H. (1977) The dynamics of cell membrane organization. In: *Dynamic Aspects of Cell Surface*

- Organization. (eds. G. Poste and G.L. Nicolson) Cell Surface Reviews, Vol. 3, pp. 1-73. Elsevier/North-Holland, Amsterdam.
350. Nicolson, G.L., Giotta, G., Lotan, R., Neri, A. and Poste, G. (1977) Modifications in transformed and malignant tumor cells. In: International Cell Biology. (eds. B.R. Brinkley and K.R. Porter) pp. 138-148. Rockefeller University Press, New York.
351. Poste, G. (1977) The cell surface and metastasis. In: Cancer Invasion and Metastasis: Biologic Mechanisms and Therapy. (ed. S.B. Day) pp. 19-47. Raven Press, New York.
352. Papahadjopoulos, D., Vail, W.J., Newton, C., Nir, S., Jacobson, K., Poste, G. and Lazo, R. (1977) Studies on membrane fusion. III. The role of calcium-induced phase changes. *Biochim. Biophys. Acta* 465, 579-598.
353. Nicolson, G. L. and Poste, G. (1976) Cell shape changes and transmembrane receptor uncoupling induced by tertiary amine local anesthetics. *J. Supramolecular Structure* 5, 65-72.
354. Poste, G. and Nicolson, G.L. (1976) Editors. Cell Surface Reviews, Volume 1. The Cell Surface in Animal Embryogenesis and Development. Elsevier/North-Holland, Amsterdam. 766 pages.
355. Poste, G. (1976) Changes in cell surface membranes associated with malignant transformation. In: Biological Handbooks: Cell Biology. (eds. P.L. Altman and D.D. Katz) Vol. 1, pp. 134-138. Federation of American Societies for Experimental Biology, Bethesda, Maryland.
356. Poste, G., Papahadjopoulos, D. and Vail, W.J. (1976) Lipid vesicles as carriers for introducing biologically active materials into cells. In: Methods in Cell Biology. (ed. D.M. Prescott) Vol. 14, pp. 33-71. Academic Press, New York.
357. D.M. Prescott) Vol. 14, pp. 23-32. Academic Press, New York.
358. Poste, G. and Papahadjopoulos, D. (1976) Fusion of mammalian cells by lipid vesicles. In: Methods in Cell Biology. (ed. D.M. Prescott) Vol. 14, pp. 1-10. Academic Press, New York.
359. Poste, G., Alexander, D. and Reeve, P. (1976) Enhancement of virus-induced cell fusion by phytohemagglutinin. In: Methods in Cell Biology. (ed. D.M. Prescott) Vol. 14, pp. 1-10. Academic Press, New York.
360. Nicolson, G. L. and Poste, G. (1976) Medical Progress. The cancer cell: Dynamic aspects and modifications in cell- surface organization. (Second of Two Parts) *New England J. Med.* 295, 253-258.
361. Nicolson, G. L. and Poste, G. (1976) Medical Progress. The cancer cell: Dynamic aspects and modifications in cell- surface organization. (First of Two Parts) *New England J. Med.* 295, 197-203.
362. Poste, G. and Weiss, L. (1976) Some considerations on cell surface alterations in malignancy. In: Fundamental Aspects of Metastasis. (ed. L. Weiss) pp. 25-47. Elsevier/North-Holland, Amsterdam.
363. Weiss, L. and Poste, G. (1976) The tumor cell periphery. In: Scientific Foundations of Oncology. (eds. T. Symington and R.L. Carter) pp. 25-35. Heinemann, London.
364. Papahadjopoulos, D., Poste, G., Vail, W.J. and Biedler, J.L. (1976) Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor cells. *Cancer Research* 36, 2988-2994.
365. II. Induction of fusion in pure phospholipid membranes by calcium ions and other divalent metals. *Biochim. Biophys. Acta* 448, 265-283.
366. Papahadjopoulos, D., Vail, W.J., Pangborn, W.A. and Poste, G. (1976) Studies on membrane fusion.
367. Papahadjopoulos, D., Hui, S., Vail, W.J. and Poste, G. (1976) Studies on membrane fusion. I. Interactions of pure phospholipid membranes and the effect of myristic acid, lysolecithin, proteins and dimethylsulfoxide. *Biochim. Biophys. Acta* 448, 245-264.
368. Jacobson, K., Derzko, Z., Wu, E.-S., Hou, Y. and Poste, G. (1976) Measurement of the lateral mobility of cell surface components in single, living cells by fluorescence recovery after photobleaching. *J. Supramolec. Structure* 5, 565-576.
369. Poste, G. and Papahadjopoulos, D. (1976) Drug-containing lipid vesicles render drug-resistant tumour cells sensitive to actinomycin D. *Nature* 261, 699-701.
370. Poste, G. and Papahadjopoulos, D. (1976) Lipid vesicles as carriers for introducing materials into cultured cells: Influence of vesicle lipid composition on mechanism(s) of vesicle incorporation into cells. *Proc. Nat. Acad. Sci. USA* 73, 1603-1607.
371. Jacobson, K., Wu, J. and Poste, G. (1976) Measurement of the translational mobility of concanavalin A in glycerol-saline solutions and on the cell surface by fluorescence recovery after photobleaching. *Biochim. Biophys. Acta* 433, 215-222.
372. Poste, G. and Nicolson, G. L. (1976) Calcium ionophores A23187 and X537A affect cell agglutination by lectins and capping of lymphocyte surface immunoglobulins. *Biochim. Biophys. Acta* 426, 148-155.
373. Nicolson, G. L., Smith, J. R. and Poste, G. (1976) Effects of local anesthetics on cell morphology and membrane- associated cytoskeletal organization in BALB/3T3 cells. *J. Cell Biol.* 68, 395-402.
374. Poste, G. and Waterson, A.P. (1975) Cell fusion by Newcastle disease virus. In: Negative Strand Viruses. (eds. B.W.J. Mahy and R.D. Barry) Vol. 2, pp. 905-922. Academic Press, London.
375. M.G. Brush and R.W. Taylor) pp. 87-108. Balliere Tindall, London.
376. Poste, G. and Waterson, A.P. (1975) Herpesvirus infection and cervical cancer. In: Gynaecological Malignancy. (eds. T.K. Chowdhury
377. Poste, G. (1975) Interaction of concanavalin A with the surface of virus-infected cells. In: Concanavalin A. (eds. T.K. Chowdhury

- and A.K. Weiss) pp. 117-152. Plenum Press, New York.
378. Weiss, L., Subjeck, J.R. and Poste, G. (1975) Some electrical properties of the peripheries of murine 3T3 cells with respect to viral transformation and reversion. *Int. J. Cancer* 16, 914-921.
 379. Poste, G., Papahadjopoulos, D. and Nicolson, G.L. (1975) Local anesthetics affect transmembrane cytoskeletal control of mobility and distribution of cell surface receptors. *Proc. Nat. Acad. Sci. USA* 72, 4430-4434.
 380. Papahadjopoulos, D. and Poste, G. (1975) Calcium-induced phase separation and fusion in phospholipid membranes. *Biophys. J.* 15, 945-948.
 381. Poste, G., Papahadjopoulos, D., Jacobson, K. and Vail, W.J. (1975) Effects of local anesthetics on membrane properties. II. Enhancement of the susceptibility of mammalian cells to agglutination by plant lectins. *Biochim. Biophys. Acta* 394, 520-539.
 382. Papahadjopoulos, D., Jacobson, K., Poste, G. and Shepard, G. (1975) Effects of local anesthetics on membrane properties. I. Changes in the fluidity of phospholipid bilayers. *Biochim. Biophys. Acta* 394, 504-519.
 383. Papahadjopoulos, D., Vail, W.J., Jacobson, K. and Poste, G. (1975) Cochleate lipid cylinders: Formation by fusion of unilamellar lipid vesicles. *Biochim. Biophys. Acta* 394, 483-491.
 384. Poste, G., Papahadjopoulos, D., Jacobson, K. and Vail, W.J. (1975) Local anaesthetics increase susceptibility of untransformed cells to agglutination by concanavalin A. *Nature* 253, 552-554.
 385. Poste, G. (1975) Production of a serine-protease with macrophage migration inhibitory factor activity by virus-transformed cells and human tumor cell lines. *Cancer Research* 35, 2558-2566.
 386. Poste, G. (1975) Production of macrophage migration inhibitory factor(s) (MIF) by virus-transformed cells. *Exp. Cell Res.* 92, 283-290.
 387. Weiss, L., Poste, G., MacKearnin, A. and Willett, K. (1975) Growth of mammalian cells on substrates coated with cellular microexudates. I. Effect on cell growth at low population densities. *J. Cell Biol.* 64, 135-145.
 388. Papahadjopoulos, D., Poste, G. and Mayhew, E. (1975) Interaction between cells, liposomes and micelles. *Biochemical Society Transactions* 3, 606-608.
 389. Mayhew, E., Poste, G., Cowden, M., Tolson, N. and Maslow, D. (1974) Cellular binding of 3H-cytochalasin B. *J. Cell Physiol.* 84, 373-382.
 390. Papahadjopoulos, D., Mayhew, E., Poste, G., Smith, S. and Vail, W.J. (1974) Incorporation of lipid vesicles by mammalian cells provides a potential method for modifying cell behavior. *Nature* 252, 163-166.
 391. Reeve, P., Hewlett, G., Watkins, H., Alexander, D.J. and Poste, G. (1974) Virus-induced cell fusion enhanced by phytohaemagglutinin. *Nature* 249, 355-356.
 392. Papahadjopoulos, D., Poste, G. and Mayhew, E. (1974) Cellular uptake of cyclic AMP captured within phospholipid vesicles and effect on cell growth behaviour. *Biochim. Biophys. Acta* 363, 404-418.
 393. Poste, G., Alexander, D.J., Reeve, P. and Hewlett, G. (1974) Modification of Newcastle disease virus release and cytopathogenicity in cells treated with plant lectins. *J. Gen. Virol.* 23, 255-270.
 394. Papahadjopoulos, D., Poste, G., Schaeffer, B.E. and Vail, W.J. (1974) Membrane fusion and molecular segregation in phospholipid vesicles. *Biochim. Biophys. Acta* 352, 10-28.
 395. Poste, G. and Reeve, P. (1974) Increased mobility and redistribution of concanavalin A receptors on cells infected with Newcastle disease virus. *Nature* 247, 469-471.
 396. Poste, G., Schaeffer, B., Reeve, P. and Alexander, D.J. (1974) Rescue of Simian virus 40 (SV40) from SV40-transformed cells by fusion with anucleate monkey cells and variation in the yield of virus rescued by fusion with replicating or nonreplicating monkey cells. *Virology* 50, 85-95.
 397. Poste, G. and Allison, A.C. (1973) Membrane fusion. *Biochim. Biophys. Acta* 300, 421-465.
 398. Poste, G. (1973) Anucleate mammalian cells: Applications in cell biology and virology. In: *Methods in Cell Biology* (ed. D.M. Prescott) Vol. 7, pp. 211-249. Academic Press, New York.
 399. Alexander, D.J., Hewlett, G., Reeve, P. and Poste, G. (1973) Studies on the cytopathic effects of Newcastle disease virus: The cytopathogenicity of strain Herts 33 in five cell types. *J. Gen. Virol.* 21, 323-337.
 400. Papahadjopoulos, D., Poste, G. and Schaeffer, B. (1973) Fusion of mammalian cells by unilamellar lipid vesicles: Influence of lipid surface charge, fluidity and cholesterol. *Biochim. Biophys. Acta* 323, 23-42.
 401. Poste, G., Greenham, L.W., Mallucci, L., Reeve, P. and Alexander, D.J. (1973) The study of cellular "microexudates" by ellipsometry and their relationship to the cell coat. *Exp. Cell Res.* 78, 303-313.
 402. Poste, G. (1973) The synthesis of surface coat materials in normal and transformed cells. *Exp. Cell Res.* 77, 264-270.
 403. Lecatsas, G. and Poste, G. (1973) Mechanism of envelopment of herpesvirus by the nuclear envelope. *Onderstepoort J. Vet. Res.* 40, 71-72.
 404. Alexander, D.J., Reeve, P. and Poste, G. (1973) Studies on the cytopathic effects of Newcastle disease virus: RNA synthesis in

- infected cells. *J. Gen. Virol.* 18, 369-373.
405. Poste, G. (1972) Electron microscope study of nuclear and nucleolar changes in cells infected with canine distemper virus. *Arch. Ges. Virusforsch* 37, 183-190.
406. Poste, G., Hawkins, D.F. and Thomlinson, J. (1972) Herpesvirus hominis infection of the female genital tract. *Obstetrics and Gynecology* 40, 871-890.
407. Poste, G., Lecatsas, G. and Apostolov, K. (1972) Electron microscope study of the morphogenesis of a new canine herpesvirus in dog kidney cell. *Arch. Ges. Virusforsch* 39, 317-329.
408. Poste, G. (1972) Characterization of a new canine herpes virus. *Arch. Ges. Virusforsch* 36, 147-157.
409. Poste, G., Reeve, P., Alexander, D.J. and Terry, G. (1972) Effect of plasma membrane lipid composition on cellular susceptibility to virus-induced cell fusion. *J. Gen. Virol.* 17, 133-136.
410. Poste, G., Reeve, P., Alexander, D.J. and Terry, G. (1972) Studies on the cytopathogenicity of Newcastle disease virus: Effect of lectins on virus infected cells. *J. Gen. Virol.* 17, 81-89.
411. Poste, G., Waterson, A.P., Terry, G. and Alexander, D. J. and Reeve, P. (1972) Cell fusion by Newcastle disease virus. *J. Gen. Virol.* 16, 95-97.
412. Poste, G. (1972) Changes in susceptibility of normal cells to agglutination by plant lectins following modification of cell coat material. *Exp. Cell Res.* 73, 319-328.
413. Poste, G. and Reeve, P. (1972) Enucleation of mammalian cells by cytochalasin B. II. Formation of hybrid cells and heterokaryons by fusion of anucleate and nucleated cells. *Exp. Cell Res.* 73, 287-294.
414. Poste, G. and Moss, C. (1972) The study of surface reactions in biological systems by ellipsometry. In: *Progress in Surface Science* (ed. S.G. Davison) Vol. 2, pp. 139-232. Pergamon Press, Oxford.
415. K. Jeon) Vol. 33, pp. 157-252. Academic Press, New York.
416. Poste, G. (1972) Mechanisms of virus-induced cell fusion. In: *International Review of Cytology* (eds. J.F. Danielli and
417. Reeve, P., Poste, G., Alexander, D.J. and Pope, G. (1972) Studies on the cytopathic effects of Newcastle disease virus: Cell surface changes. *J. Gen. Virol.* 15, 219-225.
418. Apostolov, K. and Poste, G. (1972) Interaction of Sendai virus with human erythrocytes: A system for the study of membrane fusion. *Microbios* 6, 247-261.
419. Poste, G. (1972) Enucleation of mammalian cells by cytochalasin B. I. Characterization of anucleate cells. *Exp. Cell Res.* 73, 273-286.
420. Poste, G. and Reeve, P. (1972) Agglutination of normal cells by plant lectins following infection with nononcogenic viruses. *Nature New Biology* 237, 113-114.
421. Mallucci, L., Poste, G. and Wells, V. (1972) Synthesis of cell coat in normal and transformed cells. *Nature New Biology* 235, 222-223.
422. Poste, G. and Reeve, P. (1972) Inhibition of cell fusion by local anesthetics and tranquilizers. *Exp. Cell Res.* 72, 556-560.
423. Poste, G. and Reese, P. (1972) Inhibition of virus-induced cell fusion by local anaesthetics and phenothiazine tranquilizers. *J. Gen. Virol.* 16, 21-28. 21.
424. Poste, G. (1971) The growth and cytopathogenicity of virulent and attenuated strains of canine distemper virus in dog and ferret macrophages. *J. Comp. Path.* 81, 49-54.
425. Poste, G. and King, N. (1971) Isolation of a herpesvirus from the canine genital tract: Association with infertility, abortion and stillbirths. *Veterinary Record* 88, 229-233.
426. Reeve, P., Alexander, D.J., Pope, G. and Poste, G. (1971) Studies on the cytopathic effects of Newcastle disease virus. *J. Gen. Virol.* 11, 25-34.
427. Reeve, P. and Poste, G. (1971) Studies on the cytopathogenicity of Newcastle disease virus. I. Relation between virulence, polykaryocytosis and plaque size. *J. Gen. Virol.* 11, 17-24.
428. Poste, G. and Allison, A.C. (1971) The membrane fusion reaction: A theory. *J. Theor. Biol.* 32, 165-184.
429. Reeve, P. and Poste, G. (1971) Cell fusion by Newcastle disease virus in the absence of RNA synthesis. *Nature New Biology* 229, 1957-1958.
430. Poste, G. (1971) Sub-lethal autolysis: Modification of the cell periphery by lysosomal enzymes. *Exp. Cell Res.* 67, 11-16.
431. Poste, G. (1971) Tissue dissociation with proteolytic enzymes: Adsorption and activity of enzymes at the cell surface. *Exp. Cell Res.* 65, 359-367.
432. Poste, G. and Greenham, L. W. (1971) The measurement of cell surface glycoprotein coat materials by ellipsometry. 3. Synthesis of coat materials. *Cytobios* 3, 5-15.
433. Poste, G. and Reeve, P. (1971) Formation of hybrid cells and heterokaryons by fusion of enucleated and nucleated cells. *Nature New*

Biology 229, 123-125.

434. Poste, G. (1971) Cell surface changes in virus-induced cell fusion. 2. Changes in cell coat thickness. *Microbios* 3, 55-61.
435. Poste, G. (1971) The role of lysosomes in virus-induced cell fusion. 2. Modification of the cell surface. *Microbios* 3, 105-112.
436. Greenham, L. W. and Poste, G. (1971) The role of lysosomes in virus-induced cell fusion. 1. Cytochemical studies. *Microbios* 3, 97-104.
437. Poste, G. (1970) Mixed-culture polykaryocytosis: A new form of cellular recognition behaviour. *Life Sciences* 9, 459-463.
438. Poste, G. and Greenham, L. W. (1970) The measurement of cell surface glycoprotein coat materials by ellipsometry. 2. Variation in coat thickness with cell type, tissue organization and culture conditions. *Cytobios* 2, 243-256.
439. Poste, G. (1970) The measurement of cell surface glycoprotein coat materials by ellipsometry. 1. The techniques. *Cytobios* 2, 233-241.
440. Poste, G. (1970) Cell surface changes in virus-induced cell fusion. 1. The importance of microvilli. *Microbios* 2, 227- 239.
441. Poste, G. (1970) Virus-induced polykaryocytosis and the mechanism of cell fusion. In: *Advances in Virus Research* (eds. F.B. Bang and K. Smith) Vol. 16, pp. 303-356, Academic Press, New York.
442. Poste, G. (1970) Increased growth of viruses in lymphocytes treated with heterologous antilymphocyte serum. *Transplantation* 10, 106-115.

Presentations: Visit casi.asu.edu/presentations/

1. Poste, G. [Leadership Challenges in Biomedical Innovation in an Era of Disruptive Change, Escalating Complexity and Pervasive Uncertainty](#). PUBLPOL/EMED 127/227: Health Care Leadership Winter 2023 . Stanford University School of Medicine (Jan 23, 2023)
2. Poste, G. [Global Biosecurity: Complexity, Complacency & Commitment](#). BIOE 122, EMED 122/222, PUBL POL 122/222: Global Biosecurity. Stanford University School of Medicine (Jan 23, 2023)
3. Poste, G. [Building a Collaboration Network in Transthyretin Cardiac Amyloidosis: Challenges and Opportunities](#). Updates in Cardiac Amyloidosis 2023 Conference. Mayo-ASU Health Futures Center, Phoenix, Arizona (Jan 14, 2023)
4. Poste, G. [Digital Technologies and Mental Health. ASU 8th Law & Neurosc. Conf.](#). Sandra Day O'Connor US Courthouse Phoenix (Dec 9, 2022)
5. Poste, G. [One Health and Global Biosecurity: Concept, Complexity and Commitment](#). SW One Health Symposium at the Coconino Center for the Arts. Flagstaff, Arizona (Nov 16, 2022)
6. Poste, G. Phoenix Children's Hospital (5.31.2022) [The Strategic Landscape for the US Health Ecosystem and The Evolution of Precision Oncology: Challenges and Opportunities](#). Phoenix, AZ.
7. Poste, G. Health Care Leadership (1.12.2022) [Virtual Lecture. Healthcare Leadership Class \(EMED 127/227\)](#) Stanford.
8. Poste, G. [Biosecurity: A Multi-Dimensional Challenge of Escalating Complexity and Urgency \(12 Jan 2022\) Virtual Lecture. Stanford BioSecurity Class](#)
9. Poste, G. [Characteristics, Accomplishments and Challenges of Existing Systems](#). Virtual Forum on Complex Food and Agricultural Systems: Engineering for Sustainability and Resilience. (Sep 9, 2021)
10. Poste, G. [Diagnostic Tests: The Critical Element in Pandemic Control and Global Biosurveillance Against Infectious Threats](#). (BIOE 122: BioSecurity and Pandemic Resilience) Stanford University School of Medicine Virtual (27 Jan. 2021)
11. Poste, G. [Forging Agile Regulatory Frameworks in an Environment of Accelerating Technical Change](#). PIcc -The Alliance for Digital Pathology. Virtual. (21 Jan. 2021)
12. Poste, G. [The COVID-19 Diagnostics: The Achilles Heel of SARS-CoV-2 Pandemic Control Efforts](#). ASU Diagnostics Roundtable (8 Dec. 2020)
13. Poste, G. [Planning for the Future \(Nov. 23 – Dec. 4\) Week 7](#). OVERVIEW OF BIOSECURITY GSC 598 Fall 2020
14. Poste, G. [Pressing Threats II: New and Emerging Bioweapons \(November 2020\) Week 6](#). OVERVIEW OF BIOSECURITY GSC 598 Fall 2020
15. Poste, G. [Pressing Threats I: New and Emerging Diseases and Patterns \(November 2020\) Week 5](#). OVERVIEW OF BIOSECURITY GSC 598 Fall 2020

16. Poste, G. [Biosecurity: Domestic and International Institutions \(November 2020\) Week 4](#). OVERVIEW OF BIOSECURITY GSC 598 Fall 2020
17. Poste, G. [Biological Warfare and Bioterrorism \(October 2020\) Week 3](#). OVERVIEW OF BIOSECURITY GSC 598 Fall 2020
18. Poste, G. [History of Biosecurity Threats: Pandemic and Plagues \(October 2020\) Week 2](#). OVERVIEW OF BIOSECURITY GSC 598 Fall 2020
19. Poste, G. [Biosecurity: Overview \(October 2020\)](#). OVERVIEW OF BIOSECURITY GSC 598 Fall 2020
20. Poste, G. Biosecurity: [A Multi-Dimensional Challenge of Escalating Complexity and Urgency](#). Oncology Impact Partners: Virtual Infectious Disease and Immunology Conference (Jun 14, 2020)
21. Poste, G. [The Biopharmaceutical Industry and the Healthcare Ecosystem: Challenges and Opportunities](#). ASU HSM 502 Spring 2020 McCord Hall 270 (Feb 6, 2020)
22. Poste, G. [Biosecurity: A Multi-Dimensional Challenge of Escalating Complexity and Urgency. BIOSECURITY AND BIOTERRORISM RESPONSE](#) Winter 2020. Stanford University School of Medicine, Li Ka Shing room 130 (Jan 22, 2020)
23. Poste, G. [Precision Health and Digital Health: The Inter-Dependent Strategic Drivers of Innovation in Healthcare Delivery](#). EMED 227/127: HEALTH CARE LEADERSHIP. Stanford University School of Medicine, Li Ka Shing room 130 (Jan 22, 2020)
24. Poste, G. [Development of Multi-Parameter Assays to Predict Therapeutic Response and Toxicity Risk in Immunotherapy](#). 26th International Molecular Med TRI-CON. San Francisco, CA (Mar 12, 2019)
25. Poste, G. [Biosecurity: A Multi-Dimensional Challenge of Escalating Complexity and Urgency](#). Biosecurity and Bioterrorism Response. Stanford University School of Medicine (Jan 23 2019)
26. Poste, G. [Challenges in Healthcare Innovation in An Era of Technology Acceleration, Convergence and New Value-Based Services](#). HEALTH CARE LEADERSHIP. Stanford University School of Medicine (Jan 23 2019)
27. Poste, G. [Precision Health and Digital Health: Evolving Inter-Dependencies in the Transformation of Health Care Delivery](#). Joint University Biomedical Innovation Task Force Meeting. University of Arizona (Tucson) (Oct 15 2018)
28. Poste, G. [Precision Health and Digital Health: Evolving Inter-Dependencies in the Transformation of Health Care Delivery](#). Joint University Biomedical Innovation Task Force Meeting. Scottsdale (Oct 1 2018)
29. Poste, G. [Cancer as a Complex Adaptive System: Cancer Progression, Evolutionary Dynamics and Implications for Treatment](#). BIO 302, September 26 – Lecture 10: Special Guest Lecture by Dr. George Poste. School of Life Sciences Building A, Classroom 191 (Sep 26 2018)
30. Poste, G. [Biodefense In The Age of Synthetic Biology and Precision Gene Editing](#). Global Security PLS and New Approaches to Grey-Zone Threats. Australia (Sep 11 2018 - Sep 12 2018)
31. Poste, G. [Recorded session: Biodefense In The Age of Synthetic Biology and Precision Gene Editing](#). Global Security PLS and New Approaches to Grey-Zone Threats. Australia (Sep 11 2018 - Sep 12 2018)
32. Poste, G. [Immunophenotyping to Differentiate Responder and Non-Responder Patients in Cancer Immunotherapy](#). 6th Annual Immuno-Oncology Summit. Boston, MA (Aug 28 2018)
33. Poste, G. [What Needs to Be Done Differently in Cancer Control?](#). NASEM for Cancer Control in the United States, National Academies of Science, Engineering and Medicine. Washington, DC. Washington, DC (Jun 7 2018)
34. Poste, G. [The Challenge of Comprehensive Cancer Control](#). NASEM for Cancer Control in the United States, National Academies of Science, Engineering and Medicine. Washington, DC (Jun 6 2018)
35. Poste, G. [Mapping Complex Biological Information Networks to Develop Robust Biomarkers and Define Phenotypes](#). NBDA and CAS - Biomedicine* Think Tank II: CONNECTING THE DOTS. Phoenix, AZ (May 21 2018)
36. Poste, G. [Making Precision Medicine A Reality: Molecular Diagnostics, Remote Health Status Monitoring and the Big Data Challenge](#). Sixth Annual ASU Law GETS Conference. Phoenix, AZ (May 18 2018)

37. Poste, G. [Precision Health and Digital Health: Evolving Inter-Dependencies in the Transformation of Healthcare Delivery](#). 9th Siemens Technology and Innovation Council (STIC) Meeting, Farnham Castle, Farnham, UK (Mar 7 2018)
38. Poste, G. [Cancer as a Complex Adaptive System: Cancer Progression, Evolutionary Dynamics and Implications for Treatment](#). BIO 302, Lecture 12. ASU Tempe Campus, School of Life Sciences Building A, Classroom 191 (Feb 26 2018)
39. Poste, G. Biosecurity: [A Multi-Dimensional Challenge of Escalating Complexity and Urgency](#). [Biosecurity and Bioterrorism Response, winter 2018 Course](#). Stanford University School of Medicine (Jan 24 2018)
40. Poste, G. [Wearables, Apps and Big Data in the Age of Precision Medicine](#). Spring 2018/Study Group on Biological Revolutions. Center for Law, Science and Technology (Jan 11 2018)
41. Poste, G. Cancer as a [Complex Adaptive System: Cancer Progression, Evolutionary Dynamics and Implications for Treatment](#). ASU BIO 302 Course: CANCER: Mother of All Diseases. (Sep 13 2017)
42. Poste, G. [The Complex Strategic Landscape for Precision Medicine. Keynote Address](#). Precision Medicine Leaders Summit. San Diego, California (Aug 22 2017)
43. Poste, G. [Navigating the Multi-Dimensional Complexity of Drug Pricing. CBI's Reimbursement and Access conference](#). Philadelphia, Pennsylvania (Aug 17 2017)
44. Poste, G. [Big Data and Healthcare](#). Fifth Annual Conference on Governance of Emerging Technologies: Law, Policy and Ethics. Phoenix, Arizona (May 18 2017)
45. Poste, G. [Immunophenotyping to Differentiate Responder and Non-responder Patients in Cancer Immunotherapy](#). P4: Biomarkers for Patient Selection (06) @ CHI's 13th Annual Biomarker World Congress. Philadelphia, Pennsylvania (May 3 2017)
46. Poste, G. [Understanding the Design Principles and Dynamics of Complex Adaptive Systems. Presentation to Lynx Global Intelligence](#). Arizona State University (Apr 10 2017)
47. Poste, G. [Biosecurity: A Multi-Dimensional Challenge of Escalating Complexity and Urgency](#). Stanford University (Mar 8 2017)
48. Poste, G. [The Strategic Landscape for Healthcare: Balancing Technological Innovation and the Cost of Care](#). Keynote Address for IEEE Phoenix Section, Annual Banquet. Phoenix, Arizona (Feb 11 2017)
49. Poste, G. [Navigating the Multi-Dimensional Complexity of Drug Pricing Policies](#). The National Academies of Sciences, Engineering and Medicine. Committee on Ensuring Patient Access to Affordable Drug Therapies Meeting. Stanford Law School, California (Jan 23 2017)
50. Poste, G. [PanOmics, Informatics, Economics, Ethics and Politics: The Five Forces Shaping the Evolution of Precision Medicine](#). The 4th Annual Omenn Lecture. University of Michigan Medical School. (Jan 18 2017)
51. Poste, G. [The Evolution of Precision Oncology](#). 2nd Annual West Cancer Center Oncology Symposium. Memphis, Tennessee (Nov 18 2016)
52. Poste, G. [Molecular Diagnostics: Multiplexity, Complexity and Ambiguity](#). 4th Annual CMS: Arizona State University Workshop on Molecular Diagnostics, Reimbursement and Regulation. Scottsdale, Arizona (Apr 17 2015)
53. Poste, G. [Big Data and Healthcare. AAAS Annual Meeting: Panel Presentation: Big Data-Challenges and Social Impacts](#). San Jose, California (Feb 13 2015)
54. Poste, G. [The Accelerating Trajectory of The Life Sciences: Implications for Health, Industrial Innovation and National Security. Keynote Presentation In-Q-Tel CEO Summit](#). Monterey, California (Feb 4 2015)
55. Poste, G. [From the Quest for Fire to GATTACA: Systems and Synthetic Biology as the Next Wave of Technology Disruption in the Anthropocene. The Realities & Possibilities of Systems Biology. Uniformed Services University of the Health Sciences](#). Bethesda, Maryland (Nov 3 2014)
56. Poste, G. [The Need for Critical Reassessment of Current Strategies for Cancer Therapy](#). BioConference Live on Cancer: Research,

- Discovery and Therapeutics. Virtual Presentation (Oct 17 2013)
57. Poste, G. [Confronting the Cancer Challenge: The Need for New Diagnostic and Treatment Strategies](#). Clarity Foundation Personalized Medicine in Oncology Series. Moores Cancer Center, La Jolla, California (Oct 8 2013)
 58. Poste, G. [Outpacing Infectious Diseases: Dynamic Foes and The Need for Innovation in Diagnostics, Drugs and Vaccines](#). ASU Biochemistry course BCH462. Tempe, Arizona (Sep 10 2013)
 59. Poste, G. [Opening New Investigative Directions for GBM: Confronting Complexity. Glioblastoma Multiforme \(GBM\): A Think Tank to Re-Think GBM and Setting a New Course](#). Scottsdale, Arizona (Aug 27 2013)
 60. Poste, G. [The Acceleration, Convergence and Globalization of Advanced Technologies: Escalating Complexity, Disruptive Change and New Networked Organizations](#). 3rd Annual Conference on Governance of Emerging Technologies: Law, Policy and Ethics. West Wild Horse Pass Blvd, Chandler, Arizona (May 21 2013)
 61. Poste, G. [Transformational Technologies in Biomedical R&D and Healthcare Delivery](#). Pharmaceutical Industry. Hever R&D Forum 18. Lansdowne, Virginia (May 4 2013)
 62. Poste, G. [Molecular Medicine and Digital Medicine: Disruptive Technologies in the Future Evolution of Healthcare](#). "Global Wireless Communications – Future Directions" E-health and Telecom in Healthcare IEEE WTS Conference. Chandler, Arizona (Apr 17 2013)
 63. Poste, G. [Genome Sequencing: A Status Report](#). Whole Genome Sequencing: Regulatory and Reimbursement Issues. Center for Medicaid and Medicare Services. Scottsdale, Arizona (Apr 12 2013)
 64. Poste, G. [Biosecurity: Enhancing Security in an Increasingly Complex World](#). Threat Preparation for the 21st Century: Association of University Research Parks Annual Meeting. Tempe, Arizona (Mar 6 2013)
 65. Poste, G. [Technology and Molecular Medicine: A Developer's Perspective](#). University of Chicago Public Health Law Conference: Technology and the Rising Cost of Health Care - A Paradigm Shift. Arizona State University, Tempe, Arizona (Mar 2 2013)
 66. Poste, G. [Personalized \(Precision\) Medicine: Science, Law and Health Policy. Keynote Address](#). From Bench to Society: Law and Ethics at the Frontier of Genomic Technology. UC Hastings College of the Law, San Francisco (Feb 8 2013)
 67. Poste, G. [A Status Report on Biomarkers: biomarkers that are not; standards that are forgot; and the need to transform the system we've got!](#) National Biomarkers Development Alliance (NBDA). JW Marriott Camelback Inn, Scottsdale, Arizona (Dec 13 2012)
 68. Poste, G. [Keynote Address: Computational Challenges and Opportunities in Personalized Medicine](#). INFORMS Keynote Address: Annual Meeting 2012. Phoenix, Arizona (Oct 14 2012)
 69. Poste, G. [Keynote Presentation: Integrative Omics \(iOmics\) and the Evolution of Molecular Medicine](#). 8th Annual Burrill Personalized Medicine Meeting. San Francisco, California (Sep 13 2012)
 70. Poste, G. [Presentation at DHS-DOD Meeting](#). Policy Implications of Digital Fabrication: 3D Printing and Beyond. Schaefer Institute, Washington, D. C. (Jul 26 2012)
 71. Poste, G. [Poste G. New Value Propositions in Healthcare. Burrill Meeting Cavallo Point](#). Beyond the Genome: Opportunities in Large Scale Sequencing. Cavallo Point Lodge, California (Apr 17 2012)
 72. Poste, G. [A Systems Based Approach to Cancer Informatics](#). Institute of Medicine, National Cancer Policy Forum Workshop on "Informatics Needs and Challenges in Cancer Research" Keck Center of the National Academies. Washington, D. C. (Feb 28 2012)
 73. Poste, G. ["It from Bits": Managing Massive Data as a Critical Challenge For Biomedical R&D and Healthcare Delivery](#). The Burrill Biotech 24th Annual CEO Meeting. Laguna Beach, California (Oct 17 2011 - Oct 18 2011)
 74. Poste, G. [The Increasing Importance of the Life Sciences in National Security](#). FDA MCMI Lecture Series. Silver Spring, Maryland (Oct 6 2011)
 75. Poste, G. [The Need for Urgent Reform in the Organization and Funding of Cancer Research and Clinical Trials](#). NCI Workshop. Arizona State University, Tempe, Arizona (May 19 2011 - May 20 2011)
 76. Poste, G. [The Evolution of Personalized Medicine: Opportunities and Challenges](#). Keynote Presentation: The Institute for Systems

- Biology International Symposium: Systems Biology and P4 Medicine. The Institute for Systems Biology, Seattle, Washington (May 15 2011 - May 16 2011)
77. Poste, G. [Synthetic Biology: Mapping the Design Principles of Biological Systems and the Rise of Biomimetic Engineering](#). Six Academy Synthetic Biology Symposium. The Royal Society, London (Apr 13 2011)
 78. Poste, G. [Promise, Peril, Productivity and Politics: The Strategic Environment for Healthcare R&D](#). Burrill & Company 2011 Annual Limited Partners and Advisory Board Meeting. Park City, UT (Apr 6 2011)
 79. Poste, G. [Biospecimens: A Critical Resource for Advances in Molecular Diagnostics, Imaging and Therapeutics](#). National Institutes of Health, Bethesda, Maryland (Mar 28 2011)
 80. Poste, G. [The Impact of the Life Sciences on National Security, Presentation at: Preserving National Security - The Growing Role of the Life Sciences](#). UPMC Center for Biosecurity. Washington, D.C. (Mar 3 2011)
 81. Poste, G. [The Evolution of Personalized Medicine: Opportunities and Challenges](#). 27th Montreux Symposium on LC/MS. Montreux, Switzerland (Nov 10 2010)
 82. Poste, G. [Genomics, Demographics, Epidemics, Economics and Ethics: The Complex Forces Shaping Healthcare](#). First Constantin Spiegelfeld Lecture. Research Center for Molecular Medicine Austrian Academy of Sciences, Vienna (Nov 8 2010)
 83. Poste, G. [Sustaining Healthcare Innovation in an Era of Constraint](#). The 6th Annual Burrill Personalized Medicine Meeting. Burlingame, California (Sep 27 2010)
 84. World Economic Forum Event on Mobile Health (mHealth). La Jolla, California (Jun 28 2010)
 65. Poste, G. [The Need to Build Holistic, Personalized Healthcare Delivery Systems](#). Poste, G. Vision 2020: The Need to Build Holistic, Personalized Healthcare Delivery Systems. International Health Forum. Munich (May 7 2010)
 66. Poste, G. [The Convergence of Clinical Medicine, Engineering and Computing: New Horizons in Healthcare Delivery](#). The John F. Wilkinson Memorial Lecture. Manchester Medical Society, United Kingdom (May 5 2010)
 67. Poste, G. [Technology Acceleration and Convergence: The Evolution of Novel Platforms for Improved Healthcare Delivery](#). Burrill LP & Advisory Board Meeting. Cavallo Point, California (Apr 20 2010)
 68. Poste, G. [Poste, G. The Rapidly Changing International Landscape for Advanced Research Technologies: Implications for Law Enforcement, National Security and Industrial Espionage](#). Keynote Presentation at The FBI Campus Liaison Initiative Conference. Tempe, Arizona (Mar 17 2010)
 69. Poste, G. [Addressing Technological Challenges and the Development of New Cancer Interventions](#). NCI Conference. Rethinking the Role of Infectious Agents in Cancer. Pentagon City, Virginia (Mar 16 2010)
 70. Poste, G. [Bugs, Bits and Engineering Bioforms: Good and Bad Applications and Actors](#). New America Foundation Symposium: Waring Futures: Transforming Today's Military. The Army and Navy Club, Washington, D.C. (May 24 2010)
 71. Poste, G. [Challenges and Opportunities in Cancer Detection and Diagnosis: The Need for Systems-Based Approaches For Successful Validation of Biomarkers](#). NCI Cancer Early Detection Stakeholders Meeting. Rockville, Maryland (May 21 2010)
 72. Poste, G. [Sustaining Healthcare Innovation in an Era of Constraint](#). Gold Laboratory: Somalogic Symposium. Boulder, Colorado (May 14 2010)
 73. Poste, G. [m.Health: The Emergence of a New Ecosystem for Healthcare Delivery, Global Public Health and National Security](#). Poste, G. [Bugs, Bits and Engineering Bioforms: Good and Bad Applications and Actors](#). New America Foundation Symposium: Waring Futures: Transforming Today's Military. The Army and Navy Club, Washington, D.C. (May 24 2010)
 74. Poste, G. [Challenges and Opportunities in Cancer Detection and Diagnosis: The Need for Systems-Based Approaches For Successful Validation of Biomarkers](#). NCI Cancer Early Detection Stakeholders Meeting. Rockville, Maryland (May 21 2010)
 75. Poste, G. [Sustaining Healthcare Innovation in an Era of Constraint](#). Gold Laboratory: Somalogic Symposium. Boulder, Colorado (May 14 2010)